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Role of the Notch1 Tad in Embryonic Development and Hematopoiesis
Abstract
The Notch signaling pathway is a highly conserved mode of intercellular communication used extensively
in metazoan development to direct cell fate decisions. Originally identified in Drosophila, which contains a
single receptor, mammals contain four Notch receptors (Notch1-4). Of these, Notch1 shares the greatest
homology with Drosophila Notch. Notch1 is essential for embryonic development and formation of the
vascular and hematopoietic systems. Critical Notch1 functions in the hematopoietic system include
generating the first hematopoietic stem cells (HSC) and instructing multipotent hematopoietic
progenitors to become T cells. Activating Notch1 mutations occur in multiple human cancers, including
acute T cell lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL) and mantle cell
lymphoma (MCL). While Notch1 is required to generate the earliest embryonic HSCs, additional
physiologic functions for Notch in embryonic HSC biology have not been described as constitutive panNotch deletion in early embryogenesis leads to lethality by E10.5. Ex vivo approaches suggest that Notch
signaling can expand HSCs raising the question of whether this is a physiologic Notch function. To
address this question, we generated mice that express a hypomorphic Notch1 allele. Unlike
Notch1-deficient mice, mice lacking the conserved Notch1 transcriptional activation domain (TAD) show
attenuated Notch1 function in vivo and survive until late gestation, succumbing to multiple cardiac
abnormalities. Notch1 TAD-deficient HSCs emerge from aorta-gonad-mesonephros region and are
capable of migrating to the fetal liver, but are present at a decreased frequency and impaired in their
ability to provide hematopoietic reconstitution to transplant recipients. This finding was confirmed using
an independent system where Notch signaling was conditionally ablated in fetal hematopoietic cells. In
vitro analysis of Notch1 TAD-deficient cells shows that the Notch1 TAD is important for the proper
assembly of the Notch transcriptional activation complex. Consistent with this, the TAD is also required to
promote optimal transcription of known Notch target genes in vitro. Together, these studies reveal an
essential role for the Notch1 TAD in fetal development and fetal HSC homeostasis, and identify a novel
requirement for Notch1 signaling in HSC function.
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ABSTRACT

ROLE OF THE NOTCH1 TAD IN EMBRYONIC DEVELOPMENT AND
HEMATOPOIESIS
Dawson Gerhardt
Dr. Warren Pear
The Notch signaling pathway is a highly conserved mode of intercellular communication
used extensively in metazoan development to direct cell fate decisions. Originally
identified in Drosophila, which contains a single receptor, mammals contain four Notch
receptors (Notch1-4). Of these, Notch1 shares the greatest homology with Drosophila
Notch. Notch1 is essential for embryonic development and formation of the vascular and
hematopoietic systems. Critical Notch1 functions in the hematopoietic system include
generating the first hematopoietic stem cells (HSC) and instructing multipotent
hematopoietic progenitors to become T cells. Activating Notch1 mutations occur in
multiple human cancers, including acute T cell lymphoblastic leukemia (T-ALL), chronic
lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). While Notch1 is required
to generate the earliest embryonic HSCs, additional physiologic functions for Notch in
embryonic HSC biology have not been described as constitutive pan-Notch deletion in
early embryogenesis leads to lethality by E10.5. Ex vivo approaches suggest that Notch
signaling can expand HSCs raising the question of whether this is a physiologic Notch
function. To address this question, we generated mice that express a hypomorphic
Notch1 allele. Unlike Notch1-deficient mice, mice lacking the conserved Notch1
transcriptional activation domain (TAD) show attenuated Notch1 function in vivo and
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survive until late gestation, succumbing to multiple cardiac abnormalities. Notch1 TADdeficient HSCs emerge from aorta-gonad-mesonephros region and are capable of
migrating to the fetal liver, but are present at a decreased frequency and impaired in
their ability to provide hematopoietic reconstitution to transplant recipients. This finding
was confirmed using an independent system where Notch signaling was conditionally
ablated in fetal hematopoietic cells. In vitro analysis of Notch1 TAD-deficient cells shows
that the Notch1 TAD is important for the proper assembly of the Notch transcriptional
activation complex. Consistent with this, the TAD is also required to promote optimal
transcription of known Notch target genes in vitro. Together, these studies reveal an
essential role for the Notch1 TAD in fetal development and fetal HSC homeostasis, and
identify a novel requirement for Notch1 signaling in HSC function.
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1	
  

Overview
	
  
The Notch signaling pathway is a highly conserved method of intercellular
communication used extensively in metazoan development to direct cell fate decisions
(Artavanis-Tsakonas et al. 1995). In 1917 Thomas Hunt Morgan described Drosophila
mutants that had a notched wing phenotype (Morgan 1917). Many years later, the gene
responsible for the notched wing phenotype, Notch, was cloned (Artavanis-Tsakonas et
al. 1983; Kidd et al. 1983; Wharton et al. 1985). Since its discovery, Notch signaling has
been shown to be a critical factor in processes including: morphogenesis, cell
differentiation, cell fate choices, cellular proliferation, and cell survival (ArtavanisTsakonas et al. 1999). In addition to its requirement in normal development,
dysregulation of Notch1 signaling can also result in malignancy and disease (Hori et al.
2013).
Notch signaling is initiated by the interactions of a Notch receptor with a Notch ligand on
a neighboring cell (Rebay et al. 1991). Productive Notch receptor ligand interactions
allow Notch to enter the nucleus and form a transcriptional activation complex on
consensus binding sequences, which in turn promotes transcription at target loci
(referred to in this Thesis as “CSL” or “RBPJ” binding sites) (Fortini and ArtavanisTsakonas 1994; Henkel et al. 1994; Jarriault et al. 1995). Notch signaling culminates
with the transcription of Notch target genes, which in turn influence myriad cellular
events (Kopan and Ilagan 2009). Thus, Notch proteins mediate events at both the cell
surface, where they function as receptors, and in the nucleus, where they activate
transcription, and thus are able to directly transmit extracellular signals to effect changes
in gene expression.
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Notch signaling pathway
	
  
There are four mammalian Notch genes (Notch1/2/3/4), encoding heterodimeric, singlepass transmembrane receptors and five mammalian Notch ligands (Jagged1/2, Delta
Like1/3/4), which are also transmembrane proteins (Artavanis-Tsakonas et al. 1995).
Notch ligands engage the extracellular region of a Notch receptor, which consists of
multiple epidermal growth factor (EGF) repeats (Rebay et al. 1991). Following binding of
a Notch receptor to ligand, a series of proteolytic cleavage events occurs that ultimately
liberates the intracellular region of the Notch receptor (ICN) (Ye et al. 1999). This
process requires the proteolytic activity of the γ-secretase complex (De Strooper et al.
1999). Genetic or pharmacological inhibition of γ-secretase activity, blocks all Notch
activity and phenocopies loss of Notch signaling (Donoviel et al. 1999 (Ye et al. 1999;
Fortini 2002). Once it is cleaved from the extracellular region, ICN is able to translocate
to the nucleus and associate with components of the Notch transcription complex to
activate transcription of Notch target genes (Schroeter et al. 1998; Struhl and Adachi
1998).

Notch targets include genes found in the Hairy enhance or split (Hes) family and the
Hes-related Hey family, which encode basic helix-loop-helix (bHLH) transcription factors
(Jarriault et al. 1995; Iso et al. 2003). Hes and Hey proteins can act as transcriptional
repressors and have been implicated in many developmental processes (Iso et al.
2003). In addition to the Hes and Hey families, Notch also regulates many cell type and
developmentally specific target genes (Bray and Bernard 2010). It remains unclear
which processes regulate Notch target specificity under different settings, however the
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receptor-ligand pairs expressed and the Notch interacting proteins present likely play a
large role in dictating signaling outcome (Bray and Bernard 2010).
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Figure 1-1. Overview of mammalian Notch signaling pathway. A Notch ligand
(Jagged1/2, or Delta Like 1/3/4) binds the EGF repeats in the extracellular domain of a
neighboring Notch receptor (Notch1-4). Ligand binding allows for a series of proteolytic
cleavage events, including cleavage of the intracellular region of the receptor (ICN) by
the an enzyme complex with γ-secretase activity. Following cleavage, ICN is able to
translocate to the nucleus and interact with the DNA binding protein RBPJ/CSL.
RBPJ/CSL binds to Notch target genes containing a specific sequence (depicted as
RBPJ/CSL binding site). ICN also associates with MAML to form the minimal Notch
ternary transcription complex (NTC). Association of MAML with p300 induces
transcription of Notch target genes. Additional coactivators may be recruited to augment
basal transcription.

Notch proteins do not bind DNA directly and must associate with the DNA binding
protein CSL/RBPJ (for CBF1 in humans, Suppressor of hairless in Drosophila, Lag1 in
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C. elegans and RBPJ in mice) in the nucleus to mediate gene regulation (Matsunami et
al. 1989; Fortini and Artavanis-Tsakonas 1994; Henkel et al. 1994; Christensen et al.
1996). RBPJ recognizes specific consensus DNA sequences present on genes that are
regulated by Notch (Matsunami et al. 1989; Tamura et al. 1995). In the context of Notch
signaling, it has been proposed that RBPJ is constitutively bound to Notch target genes
and acts as a transcriptional repressor in the absence of ICN (Jarriault et al. 1995; Kao
et al. 1998; Zhou and Hayward 2001). In this model, association of ICN to the DNA
bound RBPJ displaces repressors and recruits activators to promote transcription (Zhou
and Hayward 2001). In contrast, an alternate model postulates that ICN and RBPJ
interact prior to DNA binding, pre-forming the activation complex (Krejci and Bray 2007;
Castel et al. 2013). In either of these models, additional proteins and coactivators must
associate with the ICN/RBPJ dimer to activate transcription, forming the core Notch
transcription complex (NTC) (Wu et al. 2000). The minimal NTC consists of ICN,
RBPJ/CSL, and the transcriptional co-activator Mastermind like 1 (MAML-1), which
recruits the histone acetyltransferase, p300 (Wu et al. 2000). Loss or inhibition of any of
these factors attenuates the ability of Notch to activate transcription (Oka et al. 1995;
Fortini 2002; Maillard et al. 2004). Association of additional co-activators, such as
PCAF/GCN5 to the NTC, has also been reported and may augment basal transcription
of Notch genes (Kurooka et al. 1998; Kurooka and Honjo 2000; Wallberg et al. 2002).

Protein domains of intracellular Notch1 and the Notch1 TAD
Like other Notch proteins, Notch1 encodes both a transmembrane protein composed of
an extracellular, ligand interacting region, and intracellular nuclear transactivation
domain (Struhl and Adachi 1998). ICN1 is approximately 110 kDa and contains multiple,
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distinct functional domains (Aster et al. 2000; Gordon et al. 2008; Kopan and Ilagan
2009). The N-terminus of ICN1 contains an Ankyrin repeat (ANK) domain and the RAM
domain, which are responsible for RBPJ/CSL interactions. The ANK domain forms weak
contacts with RBPJ and is essential for recruiting MAML. Because of this, the ANK
domain is absolutely required for basal Notch activity (Nam et al. 2006; Wilson and
Kovall 2006; Gordon et al. 2008). At the C-terminus of ICN1 contains a sequence rich in
proline (P), glutamic acid (E), serine (S) and threonine (T) called the PEST domain that
modulates Notch protein degradation (Chiang et al. 2006; Kovall and Blacklow 2010)
and is frequently the target of gain-of-function Notch1 mutations in human T-ALL (Weng
et al. 2004) and chronic lymphocytic leukemia (Puente et al. 2011). The Notch
transcriptional activation domain (TAD) (Figure 1-2) resides between the ANK and
PEST domains and is capable of autonomous transcriptional activation (Kurooka et al.
1998; Kurooka and Honjo 2000; Fryer et al. 2002)

Figure 1-2. Schematic of TAD in intracellular Notch The intracellular domain of
Notch1-4 (ICN1-4). ICN1 has a C-terminal transcriptional activation domain (TAD). The
TAD is conserved in ICN2, but has weaker activity than the ICN1 TAD. ICN3 is reported
to have a TAD, but it is not homologous to that of ICN1 or ICN2. ICN4 has no reported
TAD
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Unlike the RAM, ANK and PEST domains, which are highly conserved, the TAD shows
substantial evolutionary divergence among the four mammalian Notch receptors
(Kurooka et al. 1998). Notch2 contains a recognizable TAD whose activity is weaker
than Notch1 (Kurooka et al. 1998). In contrast, Notch3 contains a TAD that shares
minimal function and sequence conservation with the Notch1 counterpart (Kurooka et al.
1998; Ong et al. 2006), while Notch4 lacks a TAD (Figure 1-2).
It is reported that Drosophila has a TAD, but this region does not appear to have an
important function in drosophila development (Lieber et al. 1993; Rebay et al. 1993;
Risau and Flamme 1995; Kidd et al. 1998). The region of the mouse Notch1 protein
containing the TAD shares amino acid homology the corresponding region of the human
Notch1 protein, indicating conservation of the TAD in mammals (Figure 1-3).

Figure 1-3. Amino acid alignment of mouse Notch1 TAD and human Notch1.BLAST
alignment of amino acid sequence of region corresponding to mouse Notch1 TAD to and
human Notch1 amino acid sequence

Although the Notch1 TAD was originally described as a region ICN1 that was capable of
autonomously activating transcription, it is not absolutely required for NTC function. The
transcriptional activity of the TAD was originally assessed by its ability to activate a
GAL4 luciferase reporter (containing four GAL4 binding sites) when fused to a GAL4
DNA binding domain (Kurooka et al. 1998). Further supporting a functional role for this
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domain, murine models of Notch1-induced T-ALL found the TAD to be essential for
thymocyte transformation (Aster et al. 2000). In these experiments bone marrow (BM)
progenitors were retrovirally transduced with a vector encoding ICN1 and transplanted
into recipient mice (Pear et al. 1996; Aster et al. 2000). Ectopic expression of ICN1 in
BM cells robustly induced T-ALL in vivo (Aster et al. 2000). In contrast to ICN1, retroviral
transduction of ICN1 lacking the TAD (ICN1 ΔTAD) failed to induce T-ALL, underscoring
the importance of the TAD in this Notch1 dependent event (Aster et al. 2000). This study
also found that, relative to ICN1, ICN1 ΔTAD was less competent in activating
transcription from a Notch dependent luciferase reporter (Aster et al. 2000). Importantly,
although the TAD was required for optimal reporter activation, it was dispensable for
basal Notch1 activity (Aster et al. 2000). To date, descriptions of the functional relevance
of the Notch1 TAD have been restricted to in vitro studies and systems using overexpression of the TAD. In work presented in Chapter 2 of this thesis, I present findings
illustrating important physiologic functions of the TAD in Notch1 dependent development
in vivo.
The Notch1 TAD directly interacts with the transcriptional co-activators PCAF and GCN5
(Kurooka and Honjo 2000) and since these interactions also require the ankyrin (ANK)
domain (Kurooka et al. 1998; Kurooka and Honjo 2000), they are believed to augment
Notch1-induced transcription by recruiting additional co-activators or by stabilizing the
association of p300 with the NTC (Oswald et al. 2001; Fryer et al. 2002; Wallberg et al.
2002). The intrinsic histone acetyltransferase activity PCAF and GCN5 could also
contribute to transcriptional activation (Nagy and Tora 2007).
In addition to Notch1 transcriptional activation, The TAD may also contribute Notch1
protein stability. Following the formation of a functional transcriptional complex, amino
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acids in the TAD and PEST domains are phosphorylated by MAML-associated kinases,
such as CDK8 (Fryer et al. 2004). Phosphorylation of ICN1 can target it for ubiquitination
by ligases, including FBXW7, ultimately resulting in Notch1 degradation (Fryer et al.
2002; Fryer et al. 2004; O'Neil et al. 2007; Thompson et al. 2007).

Notch1 and mammalian development
	
  
Genetic deletion of Notch1 in mice results in retarded embryonic development and death
by embryonic day 10.5 (E10.5), underscoring its essential role in embryogenesis
(Swiatek et al. 1994; Krebs et al. 2000). Furthermore, loss of Notch1 function also
impairs vasculogenesis as Notch1

-/-

mutant embryos were reported to have malformed

blood vessels in the embryo, placenta and yolk sac (Krebs et al. 2000). Vasculogenesis
is also requisite for development of the cardiovascular and hematopoietic systems (Fong
1995, Dieterlen-Lievre et al. 1993), indicating that Notch indirectly regulates these
processes in addition to known direct roles (Kumano et al. 2003; High et al. 2007; High
et al. 2009), placing Notch as a key regulator of heart and blood development. Although
Notch1 is vital to many aspects of mammalian development, special emphasis has been
placed on the role of Notch1 in development of the cardiovascular and hematopoietic
systems.

Notch1 and cardiovascular development
	
  
The mammalian vascular system is formed early during embryogenesis from
mesodermally derived cells thought to have both hematopoietic and endothelial cell
potential (Murray 1932; Palis et al. 1995; Risau and Flamme 1995). The de novo
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generation of vessels, termed vasculogenesis, is initially observed in the extraembryonic yolk sac (E7.5 in the mouse) with the formation of blood islands (Palis et al.
1995; Palis and Yoder 2001). Vasculogenesis is followed by angiogenesis, where new
vessels are formed from the endothelial cells of existing vessels, followed by
specialization of blood vessels to veins, arteries and lymphatic vessels (Risau and
Flamme 1995; Gridley 2010)
Notch signaling is essential for both vasculogenesis and angiogenesis (Gridley 2010).
Notch1, Notch4 and the ligands Dll4 and Jag1 are the primary Notch signaling
components relevant to vascular development (Krebs et al. 2000). Mice with targeted
mutations of these genes die during embryonic development and have defective
angiogenesis in the yolk sac, placenta and embryo. The vascular phenotypes common
to the aforementioned Notch mutants are characterized by a loss of arterial
differentiation along with a decrease in expression of arterial markers and an increase in
expression of venous markers (Krebs et al. 2000; Lawson et al. 2001; Fischer et al.
2004). These findings are consistent with a requirement for the Notch pathway in
arteriovenous differentiation through repression of venous cell fate. The downstream
effectors of Notch in arterial specification are thought to include the direct Notch targets
Hey1, Hey2 and EphrinB2 (Krebs et al. 2000; Lawson et al. 2001; Fischer et al. 2004). 	
  
Notch signaling is also essential for multiple aspects of heart development (High and
Epstein 2008), and mutations in the Notch pathway are associated with congenital
cardiovascular disease in humans and cardiovascular defects in mice (Li et al. 1997;
Oda et al. 1997). Notch signaling is also implicated in cardiovascular outflow tract (OFT)
formation, as mice deficient in an enzyme necessary for cleavage of ICN have OFT
defects (Nakajima et al. 2004). The importance of Notch signaling in OFT
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morphogenesis is highlighted by the OFT defects in human patients with Alagille
syndrome, a genetic disorder associated with Notch pathway mutations (Li et al. 1997;
Oda et al. 1997).
Morphogenesis of the mammalian OFT is a highly complex developmental process that
requires multiple factors and precise interactions of cardiac progenitor cells, specifically
from the cardiac neural crest, second heart field and endothelial cells (Srivastava 2006;
High and Epstein 2008; High et al. 2009; Rentschler et al. 2010). Defects in OFT
morphogenesis result in a range of cardiovascular disorders including ventricular septal
defects, double outlet right ventricle and the congenital heart disorder, tetralogy of fallot
(Jain et al. 2010).
Conditional mouse mutant models in cardiac progenitor cells have provided insight into
the specific Notch pathway components and mechanisms required for OFT formation
(Nakajima et al. 2004; High et al. 2009). High et al elegantly demonstrated that Notch
signaling, via interactions with Jag1, is required in the second heart field cells and for
migration of cardiac neural crest cells during the formation of the OFT (High et al. 2007;
High et al. 2009). The genes thought to be downstream of Notch signaling in OFT
formation include Hrt family genes (Nakagawa et al. 1999; High et al. 2007), Hes1
(Rochais et al. 2009) and Fgf8 (High and Epstein 2008; High et al. 2009). Furthermore,
Jag1 has recently been identified as a downstream Notch target in explants of neural
crest cells (Manderfield et al. 2012). We extend these findings and demonstrate (in
Chapter 2 of this thesis) that the Notch1 receptor, via the TAD, is also essential for
mouse OFT morphogenesis.
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Notch1 and hematopoietic development
	
  
The vertebrate hematopoietic system is composed of multiple specialized blood cell
types that have evolved to transport oxygen and nutrients to tissues and protect against
infection. Regardless of their lineage, all of the blood cells in the adult hematopoietic
system arise from the hematopoietic stem cells (HSCs) formed during embryonic
development (Medvinsky et al. 2011). Consequently, HSCs are tasked with both selfrenewal and the production of blood cell progenitors for the lifetime of an organism.
Notch signaling is required for HSC emergence and the development and differentiation
of multiple hematopoietic lineages (Radtke et al. 2010). Aside from generation of HSCs,
the most extensively described physiologic and pathophysiologic functions of Notch1 in
the hematopoietic system are, respectively, regulating T cell development and the
induction of T cell acute lymphoblastic leukemia (T-ALL)) (Maillard et al. 2005; Van
Vlierberghe and Ferrando 2012). 	
  
Notch1 in fetal HSC generation
	
  
HSCs produces all of the blood cells present in a developed organism, and are
functionally defined by their ability to provide long term, multi-lineage hematopoietic
reconstitution to lethally irradiated adult recipients (Spangrude et al. 1988). The HSCs
that give rise to and sustain the adult hematopoietic system are first produced during
embryonic development (Dzierzak and Speck 2008; Medvinsky et al. 2011).
Hematopoiesis occurs in at least two distinct phases during early development. These
waves of hematopoiesis are referred to as primitive and definitive hematopoiesis
(Dzierzak and Speck 2008) Primitive hematopoiesis generates the first blood cells in the
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embryo, but does not yield long term HSC activity. Definitive hematopoiesis occurs later
in embryonic development (beginning at approximately E9.5) in the aorta gonad
mesonephros region (AGM) and is responsible for producing the first bona fide HSCs
(Muller et al. 1994; Medvinsky and Dzierzak 1996; North et al. 2002). After production in
the AGM, HSCs migrate to the fetal liver (FL) at E11.5, where they mature and undergo
extensive expansion until approximately E14.5 (Ema and Nakauchi 2000). HSCs then
migrate to and complete development in the fetal BM, where they remain for the lifetime
of the organism and serve as the primary location of hematopoietic development
(Dzierzak and Speck 2008). In addition to being temporally separated, the waves of fetal
HSC development are spatially distinct and under the control of different transcriptional
regulators. While many cell autonomous and non-cell autonomous inputs control HSC
generation from the AGM, Notch1 is essential for HSC emergence (North et al. 2002;
Kumano et al. 2003; Chen et al. 2009). (Figure 1-4)
The requirement of Notch1 in HSC generation was identified in a constitutive Notch1
loss of function mouse model. In these experiments, loss of Notch1 function resulted in
the complete absence of hematopoietic cells in the AGM region (Kumano et al. 2003).
Notch2 is also expressed in the AGM, but embryos deficient in Notch2 display no
defects (Kumano et al. 2003). Notch1 deficiency also caused defective vasculogenesis
and lethality shortly after the emergence of HSCs (by E10.5). Because vascular
formation and arterial specification are necessary for hematopoiesis, this confounded the
interpretation of a cell intrinsic requirement for Notch1 in fetal HSCs (Bigas et al. 2010).
To resolve this, Hadland et al used Notch1 null embryonic stem cell chimeras to
demonstrate a cell autonomous requirement for Notch1 in generation of fetal HSCs
(Hadland et al. 2004). Further supporting a cell intrinsic requirement for Notch signaling
in fetal HSC, Jag1 mutant embryos display defective hematopoiesis, while exhibiting
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normal arterial specification (Robert-Moreno et al. 2008). Downstream effectors of Notch
in early HSCs include Hes1 and Gata2 (Robert-Moreno et al. 2005; Guiu et al. 2013).
Gata2 appears to be a Notch target in the AGM, and is also required for HSC
maintenance in the FL, but it is not known if Notch1 directly regulates Gata2 in vivo
(Robert-Moreno et al. 2005; de Pater et al. 2013). Although Notch1 is critical for
emergence of the first HSCs from the AGM, the role of Notch1 in the function of these
early HSCs and in subsequent phases of fetal HSCs development and function has not
been examined.
Notch1 and fetal liver HSCs
	
  
After formation in the AGM, HSCs migrate to the FL at approximately E11.5, where they
undergo a period of maturation and robust expansion. Functional HSCs in the fetal liver
increase about forty fold between E11.5 and E14.5, making this the greatest physiologic
expansion of HSCs during mammalian development (Ema and Nakauchi 2000). In
contrast to the adult bone marrow, where a majority of HSCs are quiescent and in the
G0 phase of the cell cycle, a majority of HSCs in the FL are actively cycling (Bowie et al.
2006; Bowie et al. 2007). In addition to proliferation, maturation of immature HSCs and
migration of hematopoietic cells from other organs, such as the yolk sac and placenta
(Samokhvalov et al. 2007; Rhodes et al. 2008), may contribute to the increase of HSCs
in the FL (Taoudi et al. 2008). The precise factors and signaling pathways directing
maturation and expansion of FL HSCs remain unknown, but multiple pieces of data
make Notch1 an attractive candidate in regulation of FL HSCs (Figure 1-4). These
include expression of the Notch ligands, Jag1 and Dll1 in the FL (Walker et al. 2001;
Cherrier et al. 2012), Notch1 expression in FL HSCs and Notch1 and activity in FL HSCs
(Oh et al. 2013).
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Notch1 and BM HSCs
	
  
The last destination of a hematopoietic stem cell in the mouse embryo is the fetal BM
(Dzierzak and Speck 2008). HSCs can be found in the BM beginning at E16.5 and, in
homeostatic conditions, remain in the BM for the lifetime of the animal (Dzierzak and
Speck 2008). Notch1 and Notch2 are expressed on BM HSCs (Walker et al. 2001;
Butler et al. 2010; Varnum-Finney et al. 2011; Oh et al. 2013), and the Notch ligand Jag1
is expressed on BM stromal cells, suggesting a role of Notch signaling in BM HSCs
(Calvi et al. 2003). In support of this, activation of Notch1 increased self-renewal and
prevented differentiation of BM HSCs, and Notch ligand stimulation effectively expanded
BM progenitors in vitro (Varnum-Finney et al. 2000; Calvi et al. 2003; Delaney et al.
2010).
There are, however, conflicting reports of the requirements for Notch signaling for the
maintenance and function of adult BM HSCs in vivo. Butler et al recently demonstrated
that ex vivo culture of BM HSCs with Notch ligand expressing endothelial cells promoted
HSC expansion and enhanced the ability of HSCs to reconstitute the hematopoietic
system of recipients that had undergone myeloablative stress (Butler et al. 2010).
Conversely, experiments by Maillard et al. and Mancini et al. showed that conditional
inhibition of Notch signaling in BM HSCs did not affect BM HSC homeostasis or function,
even in stringent conditions of hematopoietic stress and serial transplantation (Mancini
et al. 2005; Maillard et al. 2008). In these experiments, Maillard et al used a mouse with
a dominant negative from of MAML-1 (DNMAM), a pan-Notch inhibitor, that was
activated by BM specific expression of Cre (Maillard et al. 2008). In this system, the
DNMAML expression did not affect the number or function of BM HSCs, even in serial
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and competitive transplants. This finding was recapitulated in experiments with BM
specific deletion of Jag1 and Rbpj(Mancini et al. 2005; Maillard et al. 2008). Subsequent
reports asserted that in normal physiology, Notch activity is restrained in the BM by the
protein LRF, also arguing against a requirement for Notch in BM HSCs (Maeda et al.
2007). (Figure 1-4)

Notch1 and mammalian T cell development
	
  
T cell development begins with migration of hematopoietic progenitors into the thymus.
As these early T cells develop, they acquire cell surface markers that correlate to their
stage of maturation. Early in development, thymocytes are negative for the CD4 and
CD8 co-receptors and are referred to as double negative (DN) (Rothenberg and Taghon
2005). The DN subset is a heterogenous population of cells and consists of at least four
populations in sequential stages of development (DN1-DN4) (Rothenberg and Taghon
2005; Yang et al. 2010; Yashiro-Ohtani et al. 2010). Cells in the DN3 population must
undergo β selection, where successful rearrangement of the T cell receptor (TCR) β
chain allows the formation of a pre-TCR, to progress past the DN stage (Mombaerts et
al. 1992; Mallick et al. 1993). Thymocytes that survive β selection acquire expression of
both CD4 and CD8 (DP) and are subsequently subject additional developmental
checkpoints before egress from the thymus as single positive (SP) CD4 or CD8 cells
(Mombaerts et al. 1992; Mallick et al. 1993).
	
  
The requirement for Notch1 in T cell development was evinced in both gain and loss of
function Notch1 transgenic models (Pui et al. 1999; Radtke et al. 1999). Conditional
deletion of Notch1 in BM progenitors (Mx- Cre x Notch1f/f) resulted in the absence of T
	
  

16	
  

cells and increased intrathymic B-cells(Radtke et al. 1999). Conversely, retroviral Notch1
expression in adult HSCs progenitors could drive ectopic T cell development, in lieu of B
cell development, in the non T cell permissive environment of the BM (Pui et al. 1999).
Taken together, these findings argue Notch1 is necessary and sufficient for T cell
development from hematopoietic progenitors (Figure 1-4).
At the earliest stages of T cell development, Notch1 acts to inhibit alternative cell fates
and to initiate the transcription of T lineage commitment genes (Pui et al. 1999; Radtke
et al. 1999); Bell 2008). After progenitors are committed to the T lineage, Notch signaling
is again required for thymocytes to progress past the DN3 stage of development, where
it plays a critical role in orchestrating β selection (Maillard et al. 2006). Although Notch1
signaling is required for survival and metabolic function of DN3 thymocytes, it is robustly
decreased in DP cells and it remains controversial if there is an important role for the
Notch pathway at this stage (Yashiro-Ohtani et al. 2009; Dervovic et al. 2013).

	
  

17	
  

Figure 1-4 Model of Notch1in fetal and adult hematopoiesis. Notch1 is required for
emergence of HSCs from the AGM at E9.9-10.5. Lack of Notch1 also results in
embryonic lethality by E10.5. The requirement for Notch1 in HSCs after emergence from
the AGM and in the fetal liver is unknown. There are conflicting reports as to the
requirement of Notch1 in the adult BM. Notch1 is essential for T cell specification and
development in the thymus. Periods of development where Notch1 function is unknown
are labeled in red.

Although Notch1 is required to produce T cells, inappropriate activation of Notch1 can
lead to T-ALL (Reynolds et al. 1987; Ellisen et al. 1991; Pear et al. 1996). Activating
mutations of Notch1 are found in a large percentage of human T-ALLs (Weng et al.
2004). The genetic lesions that induce oncogenic Notch1 activity predominantly result in
ligand independent activation of Notch1 and increased stability of ICN1 (Weng et al.
2004). Important transcriptional targets of Notch in T cell transformation include Hes1,
IL7R, IGF1 and Myc, all of which are directly regulated by Notch (Weng et al. 2006; Van
Vlierberghe and Ferrando 2012).

	
  
	
  

18	
  

Thesis objectives
	
  
The work presented in this thesis is focused on the Notch1 TAD and its contribution to
Notch1 dependent transcription and development. To this end, I utilized a transgenic
mouse model in which a mutant Notch1 allele lacking the TAD was knocked-in to the
Notch1 locus, resulting in a mouse homozygous for Notch1 TAD deletion (ΔTAD/ΔTAD).
Based on the reported roles of the TAD in vitro and the importance of the TAD in Notch1
driven T cell leukemia, I hypothesized that the TAD was critical for optimal Notch1-driven
transcription and exerted important functions of Notch1 dependent processes in vivo.
Analysis of the ΔTAD/ΔTAD mice confirmed that in vivo loss of the TAD resulted in
hypomorphic Notch1 activity and yielded multiple developmental phenotypes. This work
allowed for a greater understanding of how the TAD impacts known Notch dependent
developmental processes, such as T cell and cardiovascular development and revealed
a novel requirement for Notch1 in development and function of HSCs.
The data presented in Chapter 2 of this thesis include broad developmental analyses of
the ΔTAD/ΔTAD mice. These data highlight the importance of the Notch1 TAD in
embryonic development, the physiologic development of thymic T cells, and formation of
the OFT. I also show that phenotypic HSCs are present in the AGM of ΔTAD/ΔTAD
embryos, suggesting that the TAD may dispensable be for Notch1 dependent generation
of HSCs from the AGM. Using biochemical and genetic models, we demonstrate that the
Notch1 TAD is necessary for optimal transcriptional activation of Notch target genes,
supporting the hypothesis that the Notch1 TAD is an important positive regulator of
Notch1 signaling in vivo. I further propose a potential mechanism for how the TAD
augments basal Notch1 transcription by stabilization of the NTC.
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As loss of the Notch1 TAD impairs, but does not abrogate Notch1 function, the
ΔTAD/ΔTAD enabled the investigation of the role Notch1 plays in fetal HSC function.
These findings are also presented in Chapter 2. By studying fetal hematopoietic cells in
ΔTAD/ΔTAD mice, I found that constitutive loss of the Notch1 TAD affected survival of
FL HSCs. I additionally demonstrate that FL HSCs from ΔTAD/ΔTAD embryos are
functionally impaired in their ability to provide hematopoietic reconstitution, implicating
Notch1 in regulating HSC function. Interestingly, BM HSCs derived from ΔTAD/ΔTAD FL
cells also exhibit secondary reconstitution defects. To confirm that the defects in fetal
HSC function observed in ΔTAD/ΔTAD cells reflected a requirement for Notch signaling
in FL HSCs, I provide findings generated from a conditional model of pan-Notch
inhibition in fetal hematopoietic cells. This work, shared by our collaborators, supports
our conclusion that Notch signaling positively impacts FL HSC function. A final aim in
Chapter 2 is the identification of Notch pathway target genes in FL HSCs.
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CHAPTER 2: The Notch1 transcriptional activation domain is required for
development and reveals a novel role for Notch1 signaling in fetal
hematopoietic stem cells

Data in this chapter is published in the manuscript:
The Notch1 transcriptional activation domain is required for development and reveals a
novel role for Notch1 signaling in fetal hematopoietic stem cells

Dawson M. Gerhardt*, Kostandin V. Pajcini*, Teresa D’altri, LiLi Tu, Rajan Jain, Lanwei
Xu, Michael J. Chen, Stacey Rentschler, Olga Shestova, Gerald B. Wertheim, John
Tobias, Michael Kluk, Antony W. Wood, Jon C. Aster, Phyllis A. Gimotty, Jonathan A.
Epstein, Nancy Speck, Anna Bigas, Warren S. Pear
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Summary
	
  
Notch1 is required to generate the earliest embryonic hematopoietic stem cells (HSC);
however since Notch-deficient embryos die early in gestation, additional functions for
Notch in embryonic HSC biology have not been described. We used a novel genetic
Notch1 mutant mouse model to address this important biological question. Unlike
Notch1-deficient mice, mice lacking the conserved Notch1 transcriptional activation
domain (TAD) show attenuated Notch1 function in vivo and survive until late gestation,
succumbing to multiple cardiac abnormalities. Notch1 TAD-deficient HSCs emerge and
successfully migrate to the FL, but are decreased in frequency by E14.5. In addition,
TAD-deficient FL HSCs fail to compete with wild type HSCs in BM transplant
experiments. This phenotype is independently recapitulated by conditional knockout of
Rbpj, a core Notch pathway component. In vitro analysis of Notch1 TAD-deficient cells
shows that the Notch1 TAD is important to properly assemble the Notch1/Rbpj/Maml
trimolecular transcription complex. Gene expression profiling of cultured FL HSCs
provided a set of genes that may be important downstream mediators of Notch signals in
HSCs. Together, these studies reveal an essential role for the Notch1 TAD in fetal
development and identify important cell autonomous functions for Notch1 signaling in
fetal HSC homeostasis.

	
  
	
  
	
  

	
  

22	
  

Introduction
	
  
Notch signaling is an evolutionarily conserved pathway that regulates binary cell fate
decisions during fetal and adult development (Artavanis-Tsakonas et al. 1999). Notch
signaling initiates when Notch receptors bind Notch ligands on a neighboring cell,
leading to cleavage and nuclear translocation of the intracellular portion of Notch (ICN)
(Schroeter et al. 1998; Struhl and Adachi 1998). Within the nucleus, Notch forms a
transcriptional activation complex through interactions with the DNA binding protein,
RBPJ and Mastermind (MAML), which functions as a co-activator via recruitment of the
histone acetyltransferase p300 (Oswald et al. 2001; Fryer et al. 2002; Nam et al. 2006;
Kovall and Blacklow 2010). Assembly and function of the Notch transcription complex
requires multiple distinct intracellular Notch1 (ICN1) domains, which play specific roles in
mediating Notch1 activity (Aster et al. 2000; Gordon et al. 2008; Kopan and Ilagan
2009). These include the N-terminal RAM domain and Ankyrin repeat (ANK) domain,
which respectively interact with RBPJ and MAML. The C-terminus of ICN1 contains a
transcriptional activation domain (TAD) and PEST sequence, which regulates protein
stability (Nam et al. 2006; Wilson and Kovall 2006; Gordon et al. 2008).

The mouse Notch1 TAD, which encompasses 203 amino acids in the C-termnius of
ICN1, was first identified by its ability to activate transcription of a GAL4 reporter when it
was fused to a GAL4 DNA binding domain. Shortly after being identified, it was found
that the TAD was required for optimal ICN1 transcriptional activity of a Notch sensitive
reporter in vitro and for ICN1-induced T-ALL in vivo (Kurooka et al. 1998; Kurooka and
Honjo 2000; Fryer et al. 2002). The TAD physically and functionally interacts with the
transcriptional co-activators PCAF and GCN5, possibly contributing to the ability of the
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TAD to enhance transcription (Kurooka et al. 1998; Kurooka and Honjo 2000). In
addition to transcriptional activation, the TAD is implicated in Notch1 protein
degradation, as it contains phosphorylation sites that may target the Notch1 protein for
ubiquitination and subsequent degradation (Fryer et al. 2002; Fryer et al. 2004).

Notch1 exerts multiple essential roles in development. Loss of either Notch1 or
components of the Notch signaling pathway leads to early embryonic demise associated
with defects in vasculogenesis, somitogenesis, and cardiogenesis (Swiatek et al. 1994;
Conlon et al. 1995; Lawson et al. 2001; Koo et al. 2005). Notch1 is also required
between days E9.5-10.5 to generate the first definitive adult HSCs in the aorta-gonadmesonephros (AGM) region (Kumano et al. 2003; Hadland et al. 2004). Definitive HSCs
are defined by their ability to provide long term, multi-lineage reconstitution to lethally
irradiated adult recipients (Dzierzak and Speck 2008). Shortly after generation, HSCs
migrate to the FL where they undergo a phase of dramatic expansion while retaining
their capacity for long-term reconstitution (Morrison et al. 1995; Ema and Nakauchi
2000). How the FL microenvironment directs HSCs to accomplish this feat remains an
important and unanswered question. While it has been argued that Notch signaling is
active in E14.5 FL HSCs (Oh et al. 2013), establishing a requirement for Notch1
functions in FL HSCs has been difficult because constitutive loss of Notch signaling
results in major vascular defects and death by E10.5 (Krebs et al. 2000),

Ultimately, HSCs migrate to the BM in late gestation, where they persist, providing a
continuous supply of blood cells through adulthood (Dzierzak and Speck 2008). As
Notch1 does not appear to be essential for adult HSC homeostasis (Mancini et al. 2005;
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Maillard et al. 2008), it is unclear whether Notch signaling provides important functions in
HSCs subsequent to establishing the earliest definitive HSC in the AGM.

Since the TAD was reported to be important in Notch1 activity in vitro and in generating
T-ALL, we hypothesized that the TAD also exerted important functions in vivo. In order
to investigate the role of the Notch1 TAD in development, we generated Notch1 knock-in
mice lacking the TAD. Loss of the Notch1 TAD was a hypomorphic mutation of Notch1 in
vivo. The TAD was critical for some Notch1 dependent developmental processes in vivo
including cardiovascular OFT formation and T cell development, but in vivo deletion of
the TAD did not phenocopy an absolute loss of Notch1 function (Swiatek et al. 1994;
Radtke et al. 1999; Krebs et al. 2000; Kumano et al. 2003)

In contrast to Notch1 null mice, mice lacking the Notch1 TAD (ΔTAD/ΔTAD) frequently
develop to late gestation and eventually succumb to multiple cardiovascular anomalies
(High and Epstein 2007; High et al. 2009). We obtained viable ΔTAD/ΔTAD embryos at
E14.5, allowing us to investigate the requirement of the Notch1 TAD in FL
hematopoiesis. Although the ΔTAD/ΔTAD embryos have an intact hematopoietic system
and HSCs successfully migrate from the AGM to the FL, the number of E14.5 FL HSCs
in ΔTAD/ΔTAD embryos was markedly reduced. Competitive transplants of highly
purified long-term FL HSCs into lethally irradiated recipient mice revealed cell intrinsic
defects of the ΔTAD/ΔTAD HSCs, a finding that was confirmed in Rbpj

f/f

x Vav-Cre

conditional knockout mice. Our findings demonstrate a previously unappreciated role for
Notch in HSC function and highlight a role of the Notch1 TAD in mammalian
development.
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Results
	
  
Generation of ΔTAD/ΔTAD mice
	
  
To determine the function of the Notch1 transactivation domain in vivo, we generated
knock-in mice expressing a Notch1 mutant lacking the TAD (ΔTAD/ΔTAD). We first
constructed a gene-targeting vector by PCR-directed deletion of the 609 base pair
sequence encoding the TAD from the mouse Notch1 gene (Fig. 2-1A). The Notch1
ΔTAD knock-in mutation was achieved by homologous recombination of the targeting
vector with the endogenous Notch1 gene in mouse ES cells. We verified deletion of the
TAD by sequencing and PCR genotyping of genomic DNA from offspring (Fig. 2-1B).
The level of Notch1 mRNA expression in mouse embryonic fibroblasts (MEF) generated
from ΔTAD/ΔTAD and wildtype (+/+) littermate controls was similar (Fig. 2-1C). In order
to confirm deletion of the Notch1 TAD had the expected effect on the structure of the
Notch1 protein, primary CD4 T cells from +/+, +/ΔTAD or ΔTAD/ΔTAD FL transplant
recipients were isolated and activated to stimulate Notch signaling. Immunoblotting for
expression of cleaved Notch1 (Val 1744) in nuclear extracts showed the presence of the
~100kD band specific for cleaved Notch1 in the +/+ and +/ΔTAD T cells, and an ~80kD
band in the +/ΔTAD and ΔTAD/ΔTAD T cells that is the expected size of a Notch1
protein bearing the ΔTAD mutation. Taken together, these results demonstrate that the
ΔTAD mutation did not impair transcription, translation, cleavage, or nuclear localization
of Notch1. However, the amount of ΔTAD protein was increased relative to wildtype
Notch1 protein (Fig. 2-1D). Given that the TAD mutation does not appear to influence
mRNA levels (Fig. 2-1C), this difference likely stems from post-transcriptional regualtion.
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Although the TAD deletion leaves intact PEST sequences that are involved in Notch1
degradation, it is also believed that sequences encoding serine amino acids in the TAD
stimulate Notch1 protein turnover (Fryer et al. 2004; Chiang et al. 2006). Mutation of
specific serine residues in the TAD did not prevent phosphorylation in an in vitro kinase
assay, but did appear to have some effect on stability of ICN1 (Fryer et al. 2004). We
tested the relative stability of ΔTAD and wild type Notch1 proteins by looking at the rate
of disappearance of the activated forms of these proteins in cells treated with a
γ −secretase inhibitor (GSI), which blocks the generation of active Notch1. Immunoblot
analysis conducted with +/+ and ΔTAD/ΔTAD cells documented the existence of a longlived pool of ΔTAD protein in the ΔTAD/ΔTAD cells (Figure 2-1E), suggesting that
decreased turnover contributes to the accumulation of ΔTAD protein.
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Figure 2-1. In vivo deletion of the Notch1 TAD (A) The Notch1 TAD was deleted by
homologous recombination using a targeting vector designed to delete the genomic
region of mouse Notch1 corresponding to the TAD (extending roughly from a Xho site
to a SacI site). (B) Deletion of the TAD (609 bp) was verified by PCR using primers
flanking the TAD. (C) Loss of the Notch1 TAD does not affect Notch1 mRNA
expression. mRNA was prepared from +/+ and ΔTAD/ΔTAD MEFs and subsequently
used for qPCR. Transcripts from +/+ and ΔTAD/ΔTAD cells were amplified with unique
primers. PCR products specific for ΔTAD/ΔTAD transcripts yielded product below the
limit of detection in +/+ cells. Primers specific for +/+ transcripts yielded product below
the limit of detection in ΔTAD/ΔTAD cells. “F”-forward primer; “R”-reverse primer. (D)
Notch1 expression. Nuclear extracts were prepared from splenic CD4+ T cells derived
from transplanted +/+, +/ΔTAD and ΔTAD/ΔTAD FL cells and used for Western blot.
Blots were probed with antibody specific for Notch1 cleaved at Val1744. β-actin is the
loading control. Deletion of the Notch1 TAD decreases Notch1 turnover. MEFs from +/+
or ΔTAD/ΔTAD were plated in equal numbers and subsequently treated with gamma
secretase inhibitors (GSI) or DMSO for 4 hours. Equal amounts of protein isolated from
nuclear extracts were used for Western blot to probe for cleaved Notch1 (Val1744).
β−actin was the loading control.
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ΔTAD is a hypomorphic Notch1 mutation
	
  
No viable ΔTAD/ΔTAD progeny were born by breeding heterozygous (+/ΔTAD) adults,
indicating the mutation resulted in death shortly after birth or during embryonic
development (Table 2-1).
+/+
E11.5 (n = 70)
Expected
17.5
Observed
18
Chi-square (2df) = 1.63, p value = 0.443

+/ΔTAD
35
39

ΔTAD/ΔTAD
17.5
13

E13.5 – 14.5
+/+
(n = 293)
Expected
75.75
Observed
73
Chi-square (2df) = 14.20, p value = 0.0008

+/ΔTAD

ΔTAD/ΔTAD

151.5
173

75.75
47

3 weeks
+/+
(n = 306)
Expected
76.5
Observed
129
Chi-square (2df) = 116.3, p value < 0.0001

+/ΔTAD

ΔTAD/ΔTAD

153
177

76.5
0

Table 2-1: Genotype of pups born to +/ΔTAD interbreedings. A chi-square test
was used to evaluate whether the observed frequencies were equal to those that
would be expected, assuming the probabilities in the three groups are given by (0.25,
0.50, 0.25). “df” – degrees of freedom

Timed matings yielded ΔTAD/ΔTAD embryos at expected Mendelian ratios at midgestation (E11.5). Genotypic analysis of E13.5-14.5 litters revealed partial embryonic
lethality of ΔTAD/ΔTAD embryos (Table 2-1), although mutant embryos that were
recovered at this time appeared grossly normal (data not shown). Histopathology of
ΔTAD/ΔTAD embryos that survive to late gestation (E18.5) revealed multiple
cardiovascular defects including abnormal OFT development and ventricular septal
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defects (Figure. 2-2A). Similar defects were observed in embryos isolated at E14.5
(data not shown). These cardiovascular abnormalities were similar to those caused by
genetic or pharmacologic inhibition of the Notch pathway and are reminiscent of
inhibiting Notch signaling in cardiac neural crest and second heart field myocardial
precursors, both of which are associated with perinatal lethality (High et al. 2007; High et
al. 2009). In contrast to ΔTAD/ΔTAD embryos, +/ΔTAD embryos were born at Mendelian
ratios and appeared normal (Table 2-1). It is interesting to note that while pan inhibition
of Notch signaling impairs OFT formation, the similar phenotype of the N1 ΔTAD/ΔTAD
embryos implies that Notch1 is the salient receptor in the OFT.
Although the failure of the Notch1 ΔTAD retrovirus to induce T cell leukemia in BM
transplants (Aster et al. 2000) suggests that deletion of the Notch1 TAD is a
hypomorphic mutation, the increased amount of the ΔTAD protein raised the possibility
that the TAD deletion might actually enhance Notch1 function in vivo. To directly address
this prospect, we used a genetic approach where Notch1 dose was titrated by crossing
+/ΔTAD mice to mice heterozygous for loss of Notch1 function (+/Notch1in32) (Swiatek et
al. 1994). We hypothesized that if deletion of the Notch1 TAD was a hypomorphic
mutation then a further decrease in Notch signaling in ΔTAD/ Notch1in32 embryos would
cause developmental abnormalities reminiscent of Notch1 loss of function mutations
(Swiatek et al. 1994). Timed matings between +/ΔTAD and +/Notch1in32 were
established and embryos were sacrificed at E9.5-E10.5, which is when mice with Notch1
loss of function mutations (Notch1in32/ in32) first exhibit developmental defects (Swiatek et
al. 1994; Oka et al. 1995). Three of the four possible genotypes from this mating develop
normally, and at mid-gestation the +/+, +/ΔTAD, and Notch1in32/+ embryos were
physiologically similar and comparable to the ΔTAD/ΔTAD embryos (Figure. 2-2B and
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data not shown). In contrast to their littermates and to the ΔTAD/ΔTAD embryos at
E9.5, all embryos (n = 3) with a Notch1 loss of function on one allele and deletion of the
Notch1 TAD on the other allele (Notch1in32/ΔTAD) were developmentally stunted and
had abnormal yolk sac vasculature and enlarged pericardial sacs, defects frequently
seen in Notch1 loss of function mutants (Swiatek et al. 1994; Krebs et al. 2000) (Figure.
2-2B, bottom right image and Appendix Table 1). We were unable to obtain
Notch1in32/ΔTAD embryos at E11.5, indicating that embryonic lethality occurred before
E11.5.
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A.

B.

Figure 2-2. Notch1 ΔTAD/ΔTAD is a hyppmorphic mutation and results in OFT
defects (A). Cross sections of WT and ΔTAD/ΔTAD hearts at E18.5. ΔTAD/ΔTAD heart
shows a ventricular septal defect (VSD). RV= right ventricle, LV = left ventricle. (B)
Deletion of the Notch1 TAD is a hypomorphic mutation. Notch1+/in32 mice were bred with
+/ΔTAD to generate Notch1in32/ΔTAD embryos. Notch in32/ΔTAD embryos were
harvested at E9.5. Control embryos from +/ΔTAD x +/ΔTAD matings were harvested at
E10.5. Normal gross development was observed in ΔTAD/ΔTAD E10.5 mutant
embryos. Retarded development and an enlarged pericardial sac were observed in
Notch1in32/ΔTAD embryos.

	
  

32	
  

The Notch1-TAD is not required for HSC emergence
	
  
Survival of the ΔTAD/ΔTAD mice to mid-gestation provided the opportunity to investigate
the potential roles of the TAD in Notch1 dependent hematopoiesis. As Notch1 is
required to generate the first definitive LT-HSCs, we investigated if loss of the Notch1
TAD prevented embryonic HSC generation. To address this, we analyzed phenotypic
HSCs in the AGM, which at E11.5 are found within a population of hematopoietic cluster
cells co-expressing the endothelial marker CD144 (VE-Cadherin) and the panhematopoietic marker CD45 (North et al. 2002; Taoudi et al. 2005). The numbers of
CD144+CD45+ cells were similar in the AGM and FL of +/+, +/ΔTAD and ΔTAD/ΔTAD
E11.5 embryos (Figures 2-3A,B). An alternative method of analyzing emerging
phenotypic HSCs from the AGM is assaying the co-expression of Kit and CD31 at the
cell surface. The Kit+CD31+ content of the AGM from the ΔTAD/ΔTAD E11.5 embryos
was similar to wildtype littermates (Yokomizo	
   and	
   Dzierzak	
   2010) (Figure 2-3C). These
data suggest that the Notch1 TAD is not necessary for either the emergence of
embryonic HSCs or their migration to the FL.
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A.

B.

C.

Figure 2-3. Characterization of E11.5 ΔTAD/ΔTAD AGM and FL cells (A) Flow
cytometry analysis of E11.5 aorta gonad mesonephros (AGM) region and E11.5 FL from
+/+ and ΔTAD/ΔTAD embryos. Cells were gated on 7-AAD- TER-119- populations.
Endothelial cells were identified as CD144+, hematopoietic progenitors are CD45+, and
HSC are CD45+CD144+.(B) Absolute numbers of cells gated as CD45+CD144+ (as
depicted in 3A) in E11.5 AGM and E11.5 FL from 3 independent experiments.
(C).Representative flow cytometry plot of cKit and CD31 in E11.5 AGM cells from +/+
and ΔTAD/ΔTAD embryos. HSCs in the E11.5 AGM are found in the CD31+cKit+
population

Another prominent developmental hematopoietic event regulated by Notch1 is the
development of T cells in the thymus. Conditional loss of Notch1 in BM progenitors
prevents progression past the double negative stage 1 (DN1)(Radtke et al. 1999).
Notch1 is again required for thymocytes to progress past the DN3 stage (Maillard et al.
2006). The hypomorphic nature of the ΔTAD/ΔTAD mutation was evident by impaired T
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cell production in the E18.5 thymus of ΔTAD/ΔTAD embryos. E18.5 thymuses from
ΔTAD/ΔTAD embryos were also hypocellular compared to littermate controls (Figure 24A) Flow cytometric analysis of thymocytes from ΔTAD/ΔTAD also revealed that the
percentage of double positive T cells was significantly decreased when compared to
littermate controls (Figure 2-4B). We also observed decreased T cells in the thymus of
irradiated recipient mice transplanted with ΔTAD/ΔTAD FL cells (Figure 2-12B)
indicating that the T cell phenotype of the ΔTAD/ΔTAD embryos reflects a cell intrinsic
defect. In contrast to homozygous loss of the TAD, we observed normal in vivo T cell
development in mice with heterozygous deletion of the TAD (Appendix Figure 1).
Together, these data also provide support that deletion of the TAD produced a
hypomorphic Notch1 allele. It is important to note that TAD is not absolutely necessary
for Notch1 mediated T cell development, as DP cells are produced in the in the thymus
and mature T cells are found in the peripheral hematopoietic organs of mice
transplanted with ΔTAD/ΔTAD HSCs (Figure 2-12B). Loss of the TAD also does not
preclude development of Thy1+ cells from HSCs cultured on Notch ligand expressing
stromal cells in vitro (Appendix Figure 2).
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A.

B.

Figure 2-4 . The TAD is required for efficient development of DP T cells in the
thymus (C) Thymuses from E18.5 embryos were isolated from +/+ (n=11), +/ΔTAD
(n=18), and ΔTAD/ΔTAD (n=7). Absolute number of thymocytes in E18.5 embryos (D)
Representative FACS plots showing percentages T-cells labeling with CD4 and/or CD8
in the +/+, +/ΔTAD, or ΔTAD/ΔTAD thymus.

Loss of the Notch1 TAD impairs formation of the Notch transcriptional activation
complex
	
  
In an effort to better define the mechanism by which the TAD regulates Notch1
dependent transcription, we performed biochemical experiments with Notch1 TAD
deficient cells. Mouse embryonic fibroblasts (MEFs) deficient in the Notch1 TAD were
used to investigate the mechanism by which the Notch1 TAD influences gene
transcription. Hes1 was found to be sensitive to Notch inhibition in MEFs, and by
performing a GSI washout assay, Hes1 was verified as a direct Notch target in MEFs
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(Figure 2-5A.). Analysis of Hes1 expression in MEFs originating from either +/+ or
ΔTAD/ΔTAD littermate embryos showed that Hes1 mRNA expression in ΔTAD/ΔTAD
MEFs was significantly lower than in +/+ MEFs (Figure 2-5B), supporting the hypothesis
that loss of the TAD negatively impacts expression of Notch targets, such as Hes1.
One mechanism that is postulated to account for the transcriptional activation by the
TAD is via association with the co-activators PCAF or GCN5 (Kurooka and Honjo 2000).
It has also been reported that the TAD can interact with PCAF to stabilize association of
p300 with the Notch transcription complex (Wallberg et al. 2002). To extend these
findings, we investigated the contribution of the TAD to the stabilization of the Notch
transcription complex. Because Hes1 was a TAD-sensitive Notch1 target in MEFs, we
used the Hes1 promoter as a model to better understand the function of the TAD.
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Figure 2-5 The Notch1 TAD influences Notch transcription complex assembly (A)
+/+ MEFs were treated for 24 hrs with gamma secretase inhibitor (GSI) or DMSO vehicle
control. GSI was washed out at 18 hrs and cells were cultured in vehicle control for an
additional 6 hrs. Hes1 mRNA was normalized to EF1a values. Graph is representative of
4 independent experiments. (B) Graph of absolute values of Hes1 mRNA from
ΔTAD/ΔTAD and +/+ MEFs. Values are normalized to EF1a from 4 independent
experiments. (C) Schematic for oligonucleotide IP. (D) +/ΔTAD nuclear lysates were
incubated with the Hes1 oligonucleotide. Western blot for cleaved Notch1 (Val1744) in
+/ΔTAD nuclear lysates (input) shows increased ΔTAD protein relative to wildtype (+)
Notch1 protein (left panel). At three concentrations (1µg, 0.75µg, 0.5µg) of
oligonucleotide, wildtype protein binding to Hes1 promoter is enriched relative to ΔTAD
protein binding. (E) Association of MAML1 to Hes1 oligonucleotide in the presence of
+/+, +/ΔTAD, or ΔTAD/ΔTAD MEF nuclear lysates. Western blot for total MAML1 (left
panel) and oligonucleotide bound MAML1 (right panel) from +/+ or ΔTAD/ΔTAD nuclear
lysates incubated with 1µg of Hes1 oligonucleotide. (F) Model of impaired formation
and/or stabilization of Notch ternary complex with loss of the Notch1 TAD.
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To determine whether absence of the Notch1 TAD influenced the binding of the Notch1
trimolecular

complex

to

DNA

targets,

we

performed

oligo-immunoprecipitation

experiments using a biotinylated oligonucleotide containing the RBPJ binding sequence
of the Hes1 promoter (Figure 2-5C) (Nam et al. 2007). Specificity of binding to the Hes1biotinylated oligonucleotide was shown by the lack of Notch1 binding after mutation of
the RBPJ binding sites (data not shown). In order to compare binding of wild type and
ΔTAD forms of Notch1 to the Hes1 promoter oligonucleotide, we used +/ΔTAD MEFs.
These cells express both forms of Notch1, with the ΔTAD protein (Figure 2-5D) being
more abundant (Figure 2-5D). Nuclear lysates from +/ΔTAD MEFs were incubated with
the biotinylated oligonucleotide to allow protein binding, and oligonucleotide-protein
complexes were captured with streptavidin-coated beads, eluted, and analyzed on
Western blots. Even though +/ΔTAD MEFs have more ΔTAD than wildtype Notch1
protein, binding of the wildtype protein to the oligonucleotide probe was greater, a
difference that became strikingly obvious when the Hes1-biotinylated oligonucleotide
was titrated out (Figure 2-5D). Similarly, association of MAML1 with the Hes1
oligonucleotide was lower in extracts prepared from ΔTAD/ΔTAD MEFs than wildtype
MEFs, despite similar levels of MAML1 protein (Figure 2-5E and Appendix Figure 3).
Association of RBPJ with the Hes1 oligonucleotide did not appear to be dependent on
the TAD (Appendix Figure 3). Thus, absence of the TAD impairs the formation of the
Notch transcriptional activation complex (Figure 2-5F).
Loss of the Notch1 TAD impairs transcription
	
  
Because the Notch1 TAD appeared to be important for stabilization of the NTC, we
hypothesized that loss of the TAD would result in decreased transcription of known
Notch target genes. To test this hypothesis, we retrovirally expressed ICN1ΔTAD in
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8946 cells, a c-Myc dependent murine T-ALL cell line (Felsher and Bishop 1999). These
cells contain a conditional doxycycline-sensitive human c-Myc transgene. In the
presence of doxycycline, expression of the human c-Myc transgenes is turned off. After
human c-Myc expression is turned, 8946 cells maintain normal growth for up to 2 days
and begin to die after approximately ~6 days in culture. It was previously shown that
expression of ICN1 in these cells induces expression of the endogenous mouse c-Myc
gene and rescues survival when the human c-Myc transgene is turned off (Weng et al.
2006). We found that expression of ICN1 in 8946 cells robustly increased expression of
many known Notch targets such as CD25, Notch1, Notch3, Dtx1, pTCRα, and c-Myc
(Figure 2-6). While overexpression of ICN1ΔTAD in 8946 cells induced transcription of
these genes relative to a vector control, the expression was significantly less than that
induced by ICN1 (Figure 2-6). Expression of ICN1ΔTAD also failed to rescue growth of
8946 cells when the human c-MYC transgene was inhibited with doxycycline,
presumably due to insufficient induction of mouse c-MYC by ICN1ΔTAD (Figure 2-7).
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Figure 2-6. The Notch1 TAD is required for optimal transcription in vitro (A)
Expression of Notch1, Notch3, c-Myc and Dtx1 in 8946 cells with overexpression of
MigR1 control, ICN1, or ICN1 ΔTAD. Data is representative of 2 independent
experiments (B) Additional experiment showing expression of CD25 and pTa in 8946
cells with overexpression of MigR1 control, ICN1, or ICN1 ΔTAD. 8946 cells were
treated with doxycycline for 24hrs prior to mRNA preparation to turn of the human c-Myc
transgene.
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Figure 2-7. The Notch1 TAD is required to rescue survival of c-Myc dependent cell
line. 8946 cells were transduced with MigR, Mig ICN1 or Mig ICN1-ΔTAD retrovirus.
Cells were treated with doxycycline (20ng/mL) at 48hrs post transduction (Day 0) for 6
days (Day 6). Cell counts were normalized to percentage of live, GFP+ cells

Notch1 signaling in FL hematopoietic stem cells
	
  
Survival of the ΔTAD/ΔTAD mice to E14.5 provided the opportunity to study Notch
function in FL hematopoiesis, which was previously difficult to study in vivo due to the
early embryonic death of Notch1 null mice. To characterize Notch1 signaling in FL
HSCs, we measured Notch1 expression and signaling in E14.5 murine FL HSCs. Using
a Notch1 mAb to measure Notch1 surface expression by flow cytometry (Figure 28A,B), we confirmed Notch1 expression on the surface of E14.5 FL hematopoietic cells
(CD45+) (Schmitt and Zuniga-Pflucker 2002; Fiorini et al. 2009). Beginning at E14.5, the
surface markers Kit, Sca1, CD150, CD48, and absence of lineage markers can be used
to stringently identify a population of long-term HSCs (Kiel et al. 2005; Kim et al. 2006),
referred to hereafter as SLAM-LSKs (Lin-Sca1+Kit+CD150+CD48-). Notch1 expression
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was greater on the LT-HSC-enriched CD45+ SLAM-LSKs than on the bulk population of
hematopoietic cells (CD45+)
Surface Notch1 expression marks cells with the potential to signal through Notch1, but
does not measure active Notch1 signaling. As Notch1 cleavage is a prerequisite for
Notch1 activation, measuring cleaved, intracellular Notch1 is a more accurate indication
of Notch activity. We used intracellular flow cytometry to measure the cleaved Notch1
intracellular peptide in E14.5 FL SLAM-LSK LT-HSCs (Figure 2-8C). The level of
expression in FL HSCs was similar to expression in DN3 thymocytes, a population
known to have robust Notch signaling, and higher than in both DP thymocytes and BM
SLAM-LSK, which are populations known to have low Notch activity (Figure 2-8D)
(Huang et al. 2003; Maillard et al. 2008; Fiorini et al. 2009; Yashiro-Ohtani et al. 2009).
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Figure 2-8. Notch1 signaling in the E14.5 FL (A) Notch1 is expressed on the surface
of FL hematopoietic progenitors and HSCs. E14.5 FLs from WT B6 embryos were
stained for SLAM LSK markers and Notch1 or isotype control antibody. Flow cytometry
plots are representative of 3 independent experiments. (B) Average fold mean
fluorescent intensity (MFI) of Notch1 expressing E14.5 FL hematopoietic cells (CD45+)
and SLAM LSKs over isotype control. (C) Notch1 is cleaved in E14.5 FL HSCs (CD45+
SLAM-LSKs). WT DN3 thymocytes, DP thymocytes and BM SLAM LSKs were used as
additional controls for detection of cleaved Notch1. Following surface staining, cells were
fixed, permeabilized and stained for intracellular Notch1 (Val 1744). (D) Graph
represents average fold MFI of intracellular Notch1 over background staining. (E)
Expression of Hes1 mRNA in sorted hematopoietic cells. All values were normalized to
Ef1α. Populations are similar to Panel C.
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To measure downstream events of Notch cleavage and further validate Notch activity,
we quantified expression of the direct Notch target, Hes1, in sorted hematopoietic cells
(Figure 2-8E). Consistent with previous studies, Hes1 mRNA was present at high levels
in DN3 thymocytes and at low levels in DP (CD4+/CD8+) thymocytes and BM SLAMLSKs (Maillard et al. 2008; Yashiro-Ohtani et al. 2009). We detected significantly higher
expression of Hes1 in E14.5 FL SLAM-LSKs compared to DP thymocytes and BM
SLAM-LSKs, although the level was not as high as in DN3 thymocytes. These data are
consistent with a recent study using a GFP allele knocked into the murine Hes1 locus,
which showed higher levels of Hes1 expression in FL HSCs compared to more
differentiated FL progenitors and BM HSCs (Oh et al. 2013). Together, these data
demonstrate that Notch1 is expressed and activated in FL HSCs, pointing to a
physiologically relevant role of Notch signaling in the FL.	
  
Notch1 ΔTAD FL LT-HSCs exhibit survival defects
	
  
After migration to the FL, HSCs continue their maturation and expansion (Ema et al
Blood 2000, Kieusseian et al Development 2012). We next asked if ΔTAD/ΔTAD FL
HSCs exhibited defects in growth and/or survival. We interrogated the capacity of
ΔTAD/ΔTAD FL cells to progress through the cell cycle by labeling with DAPI and Ki67.
We observed no defects of cell cycle entry or progression of ΔTAD/ΔTAD FL SLAMLSKs or LSKs, using this method of analysis (Figure 2-9). To assess survival, we
measured 7-AAD and Annexin V expression in FL SLAM-LSKs from +/+ and
ΔTAD/ΔTAD embryos (Figure 2-10) The percentage of early apoptotic (7AAD-/Annexin
V+) SLAM-LSKs and LSKs was significantly increased in ΔTAD/ΔTAD FL cells compared
to +/+ FL cells (Figure 2-10A,B). We observed a similar increase in Annexin V in
ΔTAD/ΔTAD LSKs (Figure 2-10C,D). These data suggest that Notch1 via the TAD
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contributes an important survival, but not proliferative function to FL LT-HSCs. Analysis
of FL histology among littermates indicated that while total FL cellularity was reduced in
E14.5 ΔTAD/ΔTAD FL, gross abnormalities were not evident (Figure 2-11). Because the
ΔTAD mutation is constitutive; however, we cannot exclude the possibility that non-cell
autonomous defects in the FL niche contribute to HSC survival.

A.

B.

C.

Figure 2-9. Cell cycle status of ΔTAD/ΔTAD E14.5 FL SLAM LSKs and LSKs (A)
Cell cycle analysis of +/+ and ΔTAD/ΔTAD E14.5 FL SLAM-LSKs. Representative flow
cytometry plot of cell cycle by DAPI and Ki-67. (B) Bar graph represents percentages of
SLAM-LSKs and (C) LSKs in each cell cycle stage from 3 independent experiments.
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A.

B.

C.

D.

Figure 2-10. Survival defects in ΔTAD/ΔTAD E14.5 FL SLAM-LSKs and LSKs
(A) Increased apoptosis in ΔTAD/ΔTAD E14.5 FL SLAM-LSKs. Representative flow
cytometry plots of Annexin V+ cells from +/+ (dotted line) and ΔTAD/ΔTAD (bold gray
line) E14.5 FL SLAM-LSKs. Annexin V expression on internal control Lin+ cells of +/+
(solid black line) and ΔTAD/ΔTAD (light grey shading) was used to determine the
positive gate for Annexin V staining. (B) Bar graph represents the normalized
percentage of Annexin V+ 7AAD- cells from E14.5 +/+ and ΔTAD/ΔTAD FL SLAM-LSKs
(n = 4). (C) Increased apoptosis in ΔTAD/ΔTAD E14.5 FL LSKs. Representative flow
cytometry plots of Annexin V+ cells from +/+ (dotted line) and ΔTAD/ΔTAD (bold gray
line) E14.5 FL LSKs. Annexin V expression on internal control Lin+ cells of +/+ (solid
black line) and ΔTAD/ΔTAD (light grey shading) was used to determine the positive gate
for Annexin V staining. (D) Bar graph represents the normalized percentage of Annexin
V+ 7AAD- cells from E14.5 +/+ and ΔTAD/ΔTAD FL LSKs (n = 4). Bar graph values were
determined by subtracting the mean percentage of +/+ Annexin V+ Lin+ cells (calculated
as % Annexin V+ cells ± SEM, which was 1.600 ± 0.147, n=4) from the mean percentage
of Annexin V+ +/+ SLAM-LSKs or LSKs, and by subtracting the mean percentage of
ΔTAD/ΔTAD Annexin V+ Lin+ cells (4.025 ± 0.728, n=4) from the mean percentage of
Annexin V+ ΔTAD/ΔTAD SLAM-LSKs or LSKs.
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A.

B.

Figure 2-11. Decreased cellularity in ΔTAD/ΔTAD E14.5 FL (A) H & E staining of +/+
and ΔTAD/ΔTAD FL. E14.5 FLs were fixed in 4% PFA and embedded in paraffin prior to
sectioning. Images are 20x and inset is 100x (B) Decreased cellularity in ΔTAD/ΔTAD
E14.5 FL. Single cell suspensions were made from individual RBCs lysed E14.5 FLs.

FL transplants indicate a role for Notch1 TAD in HSC development
	
  
To investigate a role for the Notch1 TAD in HCS function, we performed FL transplants
from E14.5 ΔTAD/ΔTAD embryos. Unsorted E14.5 FL cells from +/ΔTAD or
ΔTAD/ΔTAD (C57BL/6 CD45.2+) were transplanted into congenic, lethally irradiated SJL
(B6-Ly5.2/Cr CD45.1+) recipients (Figure 2-12A). Cells expressing CD19, CD4, CD8 or
Gr1 were present in recipients of ΔTAD/ΔTAD E14.5 FL cells; however, there was a
partial block in thymocyte development from the CD4-CD8- double negative (DN) to the
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CD4+CD8+ double positive (DP) stage, as evidenced by the decreased percentage and
absolute numbers of CD45.2-derived cells in the thymus (Figure 2-12B,C). We did not
find differences in the number or percentage of splenic CD19+ or Gr1+ cells (Figure 212B,C). The T cell findings were reminiscent of conditional Notch1 and Rbpj knockout
alleles (Wolfer et al. 2002; Tanigaki et al. 2004) and consistent with the hypomorphic
nature of the ΔTAD allele.

Figure 2-12. TAD-deficient FLs provide long-term multilineage reconstitution to
irradiated recipients. (A) Schematic for non-competitive E14.5 fetal liver transplant. (B)
Multilineage reconstitution of primary recipients by ΔTAD/ΔTAD E14.5 FL cells.
Representative flow cytometry plots from the thymus and spleen of +/+ or ΔTAD/ΔTAD
reconstituted recipients at 16 wks. (C) Absolute numbers of DP (CD4+CD8+) CD45.2+
cells in the thymus and CD19+CD45.2+, Gr1+CD45.2+ cells in spleen of primary
transplant recipients (16 weeks) Transplant was non-competitive transplant of +/+ or
ΔTAD/ΔTAD E14.5 FL cells into into lethally irradiated CD45.1+ recipients.
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While multi-lineage reconstitution of recipient mice verified the existence of HSCs in the
FLs of ΔTAD/ΔTAD donors, the percentage (Figure 2-13A) and absolute numbers
(Figure 2-13B) of CD45.2+ cells in the bone marrow were significantly reduced when
compared to reconstitution by +/+ and +/ΔTAD FL littermate controls. It is unlikely that
the decrease of ΔTAD/ΔTAD-derived cells in the periphery was due to aberrant HSC
self-renewal at the expense of progenitor differentiation or retention of cells in the BM, as
CD45.2+ HSCs did not accumulate in the BM of recipient mice (Figure 2-13C,D).
The ability of ΔTAD/ΔTAD FL cells to home to recipient BM and produce lymphoid and
myeloid lineages demonstrates that functional hematopoietic stem cells can be
generated even in the absence of the TAD, although loss of the TAD may negatively
impact the efficiency of repopulation. To further explore defects in the ΔTAD/ΔTAD FL
HSCs, we performed competitive whole FL transplants, which tests the ability of these
cells to compete against wildtype FL counterparts. We transplanted unfractionated FL
cells from E14.5 +/ΔTAD or ΔTAD/ΔTAD (CD45.2+) at a 1:1 ratio with competitor
CD45.1+ E14.5 FL cells. When compared to reconstitution by +/ΔTAD FL derived cells,
we observed minimal contribution to hematopoietic cells in the peripheral blood from
ΔTAD/ΔTAD FL derived cells (Figure 2-14).
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Figure 2-13. Impaired reconstitution in non competitive transplant of ΔTAD/ΔTAD
FL cells (A) 2 x 106 E14.5 FL cells from B6 (CD45.2+) +/+, +/ΔTAD or ΔTAD/ΔTAD
embryos (as depicted in schematic from Figure 3-5) were transplanted into lethally
irradiated SJL (CD45.1+) recipients. Bar graph represents mean reconstitution at 16
weeks in BM, measured by percentage of CD45.2 cells. (B) Absolute numbers of
CD45.2+ cells in the BM, Spleen and thymus of primary transplant recipients (16 weeks).
(C) Absolute numbers of CD45.2+ SLAM LSKs in the bone marrow of primary transplant
recipients. +/+ or ΔTAD/ΔTAD E14.5 FL cells were transplanted into lethally irradiated
CD45.1+ recipients. (C) Presence of phenotypic HSCs, but no aberrant accumulation of
SLAM LSKs in the BM following transplant of ΔTAD/ΔTAD FL cells. Representative
FACS plots of LSK and SLAM-LSK populations in the BM at 16 weeks post-transplant.
(C) Absolute # of SLAM LSKs in the BM following transplant of ΔTAD/ΔTAD FL cells
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Figure 2-14 Competitive reconstitution defect of ΔTAD/ΔTAD FL cells. 1 x 106
E14.5 FL cells from B6 (CD45.2+) +/ΔTAD or ΔTAD/ΔTAD embryos were transplanted in
competition with 1 x 106 WT CD45.1+ E14.5 FL cells into lethally irradiated SJL CD45.1
recipients. Bar graph represents mean reconstitution at 16 weeks in peripheral blood,
measured by the percentage of CD45.2 cells.

The observed defects in both the non-competitive and competitive transplants of
ΔTAD/ΔTAD FL cells could be due to several developmental defects, such as decreased
frequency of HSCs, impaired function of HSCs, or a combination of both. To ascertain
the basis for this defect, we first assessed the frequency of ΔTAD/ΔTAD FL HSCs. The
frequency of FL LT-HSCs was quantified by flow cytometric analysis of cells expressing
SLAM-LSK markers, which phenotypically mark a population of cells enriched for HSCs
(Figure 2-15A). We observed a significant decrease in the ΔTAD/ΔTAD FL LSK and
SLAM-LSK cells in the CD45+ population, suggesting that los of the TAD leads to a
decrease in FL HSCs (Kiel et al. 2005) (Figure 2-15B,C). Taken together with the
increased Annexin V expression on ΔTAD/ΔTAD LSKs and SLAM-LSKs, we conclude
that the drastic reduction of ΔTAD/ΔTAD LSKs and SLAM-LSKs is secondary to
apoptosis of these cells. The dramatic decrease in the SLAM-LSK HSCs in the
ΔTAD/ΔTAD FL also provides a potential explanation for the competitive disadvantage
observed in the whole FL transplants.
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Figure 2-15. Decreased frequency of phenotypic HSCs in ΔTAD/ΔTAD E14.5 FL (A)
SLAM-LSK gating strategy to identify LT-HSCs. (B) Percentage of LSK from +/+,
+/ΔTAD or ΔTAD/ΔTAD E14.5 FL cells. All cells were first gated on DAPI-CD45.2+. (C)
Number of LSK (left panel) SLAM-LSK (right panel) per 106 cells from +/+, +/ΔTAD or
ΔTAD/ΔTAD E14.5 fetal livers.
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Competitive SLAM-LSK FL transplants reveal cell-intrinsic defects in ΔTAD/ΔTAD
FL HSCs
	
  
Although the ΔTAD/ΔTAD FL HSCs exhibited reconstitution defects at the population
level, it was critical to determine whether this defect was due to a cell intrinsic
shortcoming in the HSC population or to other potential developmental abnormalities. To
discriminate between these possibilities, we performed competitive transplants with
purified SLAM-LSK FL HSCs. We sorted CD45.2+ SLAM-LSKs from the FLs of E14.5
+/+, +/ΔTAD, and ΔTAD/ΔTAD littermates (Figure 2-16). To simplify the description of
the experimental design, CD45.2+ FL SLAM-LSKs are referred to as donor cells. For
competitor cells, we sorted CD45.1+/CD45.2+ SLAM-LSKs from adult BM. SJL (B6Ly5.2/Cr CD45.1+) mice were lethally irradiated and transplanted with an equal ratio of
350 donor FL CD45.2+ SLAM LSK to 350 BM competitor CD45.1/CD45.2 BM SLAM
LSKs, along with a protective dose of helper splenocytes (Figure 2-16A). The
reconstitution capacity of donor cells was defined by the percentage of CD45.2+ cells in
the peripheral blood of transplant recipients. We found that the ΔTAD/ΔTAD FL SLAMLSKs were markedly deficient in reconstituting irradiated hosts when placed under
competitive stress (Figure 2-16B,C). In addition to the ΔTAD/ΔTAD FL cells, the
+/ΔTAD SLAM LSK FL cells also significantly underperformed in competitive
reconstitution assays (Figure 2-16B,C). Defects in fetal +/ΔTAD HSCs were only
apparent in conditions of competitive stress, as both FL and AGM cells provided
comparable reconstitution as +/+ cells in a non-competitive setting (Figure 2-13 and
Appendix Figure 4 and 5).
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Figure 2-16. Impaired competitive reconstitution by ΔTAD/ΔTAD FL HSCs (A)
Schematic representation of competitive transplant from B6 (CD45.2+) FL E14.5 +/+,
+/ΔTAD, ΔTAD/ΔTAD FL and BM cells from adult B6/SJL F1 (CD45.1/CD45.2) mice
were FACS sorted for SLAM-LSK. 350 FL SLAM-LSKs and 350 BM SLAM LSKs were
transplanted in competition (1:1) into lethally irradiated CD45.1+ recipients. (B)
Representative flow cytometry plots from peripheral blood (16 weeks post-transplant) of
recipients showing reconstitution by CD45.2+ cells. (C) Donor cell reconstitution at week
16 was measured by CD45.2 percentage in peripheral blood of recipients. Plot of data
points is from 5 independent experiments.
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Figure 2-17. Functional HSCs reside within the LSK population of ΔTAD/ΔTAD
E14.5 FL cells A) Unfractionated or LSK-depleted (by FACS sorting) E14.5 FL cells
from +/+ and ΔTAD/ΔTAD embryos were transplanted into lethally irradiated CD45.1
recipients. (B) Long-term reconstitution, measured by flow cytometry of CD45.2+ cells in
peripheral blood was observed in recipients +/+ or ΔTAD/ΔTAD cells. Lin-Kit-Sca1- (LSKdepleted) FL cells were unable to reconstitute irradiated recipients (bottom panel of flow
cytometry plots).
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Furthermore, the use of purified HSCs from the FL of ΔTAD/ΔTAD embryos avoids the
potential confounding effects of developmental abnormalities associated with this
genetic background and serves to highlight a novel role for Notch1 signaling in FL HSC
maturation and function. To rule out the possibility that we were excluding ΔTAD/ΔTAD
FL HSCs in the populations we were selecting for transplants, we transplanted unsorted
and LSK-depleted cells from ΔTAD/ΔTAD FLs directly into irradiated recipients.
Unsorted ΔTAD/ΔTAD FL cells provided multilineage reconstitution, while +/+ and
ΔTAD/ΔTAD FLs depleted for LSK cells did not (Figure 2-17).
As these data suggested an important cell autonomous defect in HSC function in the
ΔTAD mice, we performed secondary BMTs in mice that had received unfractionated
E14.5 FL cells (Figure 2-18). Donor-derived (1000 CD45.2+ HSCs from ΔTAD/ΔTAD or
+/+) CD45.2+ SLAM-LSKs were sorted from the BMs of primary recipients 16 weeks
post-transplant and were transferred into secondary irradiated hosts (Figure 2-18A).
When we analyzed the peripheral blood of the secondary hosts for the presence of
CD45.2+ cells, we found a significant decrease in the ability of the ΔTAD/ΔTAD SLAM
LSKs to reconstitute the secondary hosts (Figure 2-18B). These data suggest that
Notch1, via the TAD, is required for both the survival of HSCs in the FL and for optimal
function of FL HSCs in the transplant setting.
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Figure 2-18. ΔTAD/ΔTAD derive BM HSCs are impaired in secondary transplant (A)
Schematic for non-competitive secondary transplant of +/+ or ΔTAD/ΔTAD derived BM
SLAM LSKs. 1000 sorted donor derived CD45.2+ SLAM LSKs were harvested from the
BM of mice 16 weeks after receiving a primary transplant of 2 x106 +/+ or ΔTAD/ΔTAD
unsorted FL cells (donor cells expressed CD45.2) (B) Reconstitution (measured by
%CD45.2) of the peripheral blood (4 week and 8 weeks) of secondary transplant
recipients from 3 independent experiments.
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Figure 2-19. Schematic of Rbpj deletion in fetal hematopoietic cells. Rbpj is excised
from cells with loxP flanked alleles of Rbpj (Rbpj f/f) after expression of Cre recombinase.
Cre expression is restricted to hematopoietic, Vav1 expressing, cells. Cre expression
also excises a stop codon upstream of of yellow fluorescent protein (YFP), allowing Cre
expression to be tracked by fluorescence. Control cells (Rbpj +/+) express Cre and YFP,
but retain functional Rbpj. Experiments performed and data provide by Teresa D’Altri.

Competitive transplants reveal cell-intrinsic defects in Rbpj f/f x Vav-Cre FL HSCs
	
  
Our findings in the Notch1 ΔTAD model suggested that Notch1 is critical for FL HSC
homeostasis. To verify this finding, we used an additional genetic model in which RBPJ
is conditionally deleted in fetal HSCs (schematic is depicted in Figure 2-19).
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RBPJ is the DNA binding protein that mediates Notch transcriptional activation (Tamura
et al. 1995) and constitutive loss of Rbpj mirrors loss of Notch function (Oka et al. 1995).
Specific hematopoietic deletion of Rbpj was attained by breeding mice with floxed Rbpj
alleles to mice expressing Cre recombinase under the regulation of Vav1 genetic
elements. Vav1 expression is restricted to hematopoietic cells and the Vav-Cre
transgene becomes active between E12.5-E14.5 (Ogilvy et al. 1999; Stadtfeld and Graf
2005), thus restricting the deletion of RPBJ to hematopoietic cells after HSC emergence
without affecting embryonic survival or the generation of Notch1-dependent HSC
precursors. We performed a transplant of 10,000 unsorted E14.5 FL cells from Rbpj
Vav-Cre Rosa26YFP or Rbpj

f/f

+/+

;

; Vav-Cre Rosa26YFP embryos in competition with

200,000 congenic BM competitors (Figure 2-20A) (Experiment was performed by
Teresa D’Altri and contributed with permission by Teresa D’Altri and Anna Bigas).
Consistent with the competitive transplants of the ΔTAD/ΔTAD FL HSCs, Rbpj f/f; VavCre FL cells exhibited a competitive reconstitution defect as indicated by the low
percentage of YFP+ cells in the peripheral blood or BM of transplant recipients 16 weeks
post-transplant (Figure 2-20B). These results confirm a novel and specific, cell-intrinsic
role for Notch signaling in FL HSC function. In contrast to ΔTAD/ΔTAD FL, there was not
a reduction in percentage (Figure 2-21A) or number (not shown) of SLAM-LSKs or
increased Annexin V on cells in the SLAM-LSK compartment of Rbpj f/f; Vav-Cre E14.5
FL (Figure 2-21B).
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Figure 2-20. Impaired competitive reconstitution of Rbpj deficient E14.5 FL cells(A)
Competitive reconstitution of Rbpj-deficient FL hematopoietic cells. E14.5 FL cells from
Rbpj f/f ; Vav-Cre Rosa26YFP and Rbpj +/+ ; Vav-Cre Rosa26 YFP control embryos were
transplanted in competition with CD45.1/CD45.2 adult BM cells at a ratio of 10,000 FL
cells: 200,000 BM cells. (B) Donor cell reconstitution was measured by the percentage
of YFP+ cells in the blood and BM at 16 weeks post-transplant.
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Figure 2-21 Conditional deletion of Rbpj does not effect FL HSC number or
survival. (A) Gating and percentage of E14.5 FL LSK (left) and FL SLAM-LSK (right)
from Rbpj+/f ; Vav Cre YFP+ and Rbpjf/f ; Vav Cre YFP+ embryos. (B) Representative
Annexin V staining in E14.5 FL SLAM-LSKs from Rbpj+/f ; Vav Cre YFP+ and Rbpjf/f ; Vav
Cre YFP+.

	
  

62	
  

Notch targets in FL HSCs
Although multiple direct targets of Notch1 in T cells are known, the identity of genes
regulated by Notch in fetal HSCs is not known. To identify potential targets of Notch in
FL SLAM-LSKs, we used an ex vivo system, in which SLAM-LSK cells were cultured for
short periods on OP9-DL1 stromal cells, which express the Notch ligand DL1, (Holmes
and Zuniga-Pflucker 2009) prior to harvest for RNA preparation and microarray analysis.
The goal with this approach was that use of OP9-DL1, short culture periods (4 hrs and
10 hrs) would promote expression of downstream Notch target genes in HSCs, but not
induce differentiation. Wild type (C57BL/6) E14.5 FL cells were cultured on OP9-DL1
cells, with one set receiving control vehicle control (DMSO) treatment (referred to as
“Notch on” in Figure 2-22) while the other was treated with GSI for either 4hrs or 10hrs
(referred to as “Notch off” in Figure 2-22). Following treatment, SLAM-LSK HSCs
were sorted and microarray-based gene expression profiling was performed on mRNA
from these cells (Figure 2-22).
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Figure 2-22. Identification of putative Notch target genes in FL HSCs. (A) B6 E14.5
FL cells were cultured on OP9-DL1 cells for the times indicated (4hr or 10hr) in the
presence of vehicle control (DSMO) in the “Notch on” state or γ-secretase inhibitor (GSI)
in the “Notch off” state. SLAM-LSKs were sorted from the cultured cells and RNA
obtained from the SLAM-LSKs was used for microarray analysis. Selected genes with
decreased expression in the presence of GSI are shown. * denotes genes with
decreased expression in both 4 hr and 10 hr GSI culture. q value(%) is used to represent
false discovery rate.(B) qPCR validation from E14.5 FL SLAM LSKs for genes Hes1,
Jag1 (Jagged1) and Itgal (Integrin-α/LFA-1) All mRNA values were normalized to Ef1α .
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To ensure continued inhibition of Notch signaling during the preparation and sort, DMSO
or GSI was added to all staining cocktails and sort buffers. The gene most prominently
decreased by GSI in the SLAM LSKs was Hes1, a known direct Notch target gene. This
finding is consistent with many recent studies that have identified Hes1 expression in
E14.5 FL HSCs (McKinney-Freeman et al. 2012; Guiu et al. 2013,(Oh et al. 2013), and
suggests that it may be downstream of Notch activation in FL HSCs. Hes1 is known to
have important functions in HSC fate specification and maintenance of T-ALL cells
(Wendorff et al. 2010; Guiu et al. 2013), both of which may be relevant to the
phenotypes observed in the ΔTAD FL HSC. Competitive transplant of Hes1 deficient
SLAM-LSKs did not reveal reconstitution defects at an early time point (4 weeks),
however, suggesting that additional Notch targets may be important in FL HSC function
(Appendix Figure 6 and 7). We also identified ItgaL (LFA-1), Jag1, FasL (Fas Ligand),
and endophilin A3 (Sh3Gl3) as sensitive to Notch inhibition under both 4hr and 10hr GSI
conditions.

Figure 2-23 Jag1 expression is decreased in ΔTAD/ΔTAD MEFs. qPCR of Jag1 in
+/+ and ΔTAD/ΔTAD MEFs.
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These results were validated independently by qPCR on multiple biological replicates of
the SLAM-LSK microarray experiment (Figure 2-23 and Appendix Figure 8). While we
were not able to test expression of these genes in ΔTAD FL HSCs, we found that both
Hes1 (Figure 2-5) and Jag1 mRNA (Figure 2-23) were decreased in ΔTAD derived
MEFs. The Notch ligand Jag1 was identified as an important Notch target in cardiac OFT
development (High et al. 2009) and ItgaL may have functions in cell migration and
adhesion (Peter and O'Toole 1995; Torensma et al. 1996; Asaumi et al. 2001)

Discussion
	
  
Successful ex-vivo HSC expansion has been proven to be a considerable challenge,
primarily due our limited understanding of the mechanisms regulating HSC expansion in
vivo. The complicated origins and migratory development of HSCs have made this
difficult task even more daunting, further confounded by the fact that the BM, the site of
harvest for clinically relevant HSCs, provides a niche that supports adult HSC
quiescence (Essers et al. 2009; Seita and Weissman 2010). In contrast to the adult BM,
the FL is an important developmental site of HSC expansion (Ema and Nakauchi 2000),
however, only a handful of factors, such as Sox17, Pu.1, Hoxa9, Gata2 and Cited2 have
been shown to be critical for FL HSC homeostasis (Kim et al. 2004; Argiropoulos and
Humphries 2007; Chen et al. 2007; Kim et al. 2007; de Pater et al. 2013). Gata2 is
downstream of Notch1 in the AGM and is critical for HSC emergence in the AGM and
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HSC survival in the FL (de Pater et al. 2013). It is interesting to speculate that Notch1
may regulate Gata2 in the FL. Notch1 was recently identified as a direct Sox17
transcriptional target in the hemogenic endothelium and is downstream of Sox17 in
arterial specification (Clarke et al. 2013; Corada et al. 2013). Although Notch1 has been
proposed to contribute to ex-vivo HSC expansion, and is expressed in the FL (Walker et
al. 2001; Butler et al. 2010; McKinney-Freeman et al. 2012; Oh et al. 2013) it is not
known whether Notch signaling has a role in the physiological expansion of HSCs. There
are conflicting reports regarding the need for Notch in BM HSC homeostasis. To date,
the only known physiologic requirement for Notch in HSCs is in the emergence of the
first definitive HSC in the ~E9.5 AGM.

We now report that Rbpj-dependent Notch1 signaling is a key regulator of FL HSC
homeostasis. Previous studies of Notch signaling in fetal HSCs were hampered by the
embryonic lethality that occurred prior to the onset of FL hematopoiesis. By deleting the
Notch1 TAD, we generated a hypomorphic allele that allowed us to assay the
requirement for Notch1 signaling in FL HSCs. Constitutive loss of the TAD resulted in a
decrease of phenotypic HSCs in the FL, primarily due to increased apoptosis. In addition
to the requirement of Notch signaling in FL HSC survival, our studies of purified ΔTAD
FL HSCs revealed a separate requirement for Notch1 signaling in FL HSC function. In
these experiments, we sorted phenotypic FL LT-HSCs at a time in embryonic
development (E14.5) after HSCs have successfully migrated to the FL and begun their
maturation and expansion. We found that both homozygous and heterozygous loss of
the Notch1 TAD impaired the function of purified FL HSCs in competitive reconstitution
assays and homozygous loss of the TAD also impaired HSC function in serial
transplantation assays (depicted in Figure 2-24). These assays utilized purified FL
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SLAM-LSK cells; thus, we believe the observed reconstitution defects are intrinsic to FL
HSCs and inherent to the ΔTAD mutation. An interesting possibility is that BM HSCs
derived from ΔTAD/ΔTAD FL could retain some genetic imprint acquired through the
course of embryonic HSC development in TAD deficient cells.

Figure 2-24. Model of ΔTAD/ΔTAD HSC function. Loss of the TAD impairs
transcription of Notch1 targets, but does not preclude generation of HSCs in the AGM or
migration of HSCs to the FL. TAD deficient HSCs are decreased in the E14.5 FL and fail
to compete with wild type FL cells in hematopoietic reconstitution. In non-competitive
transplants, ΔTAD/ΔTAD FL cells can provide primary hematopoietic reconstitution, but
ΔTAD/ΔTAD derived BM HSCs are defective in secondary transplants compared to BM
HSCs derived from +/+ FL cells (rightmost blue panels).
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The requirement for Notch in FL HSC function was corroborated by experiments using
RBPJ-deficient FL hematopoietic cells (Rbpj

f/f

; Vav-Cre Rosa26YFP), where we

observed similar defects in competitive reconstitution assays. The Vav-Cre mediated
deletion of RBPJ occurs after hematopoietic stem cells have migrated to the FL; thus,
the reconstitution defect reflects a requirement for Notch signaling in the FL and not in
the generation of HSCs. Deletion of Rbpj did not appear to affect survival of FL HSCs.
This could indicate that the apoptosis observed in ΔTAD/ ΔTAD FL HSCs was non-cell
autonomous or that Notch is required for survival prior to deletion of Rbpj. Together,
these two different murine models provide strong evidence for cell autonomous functions
of Notch signaling in FL HSC homeostasis.

While we focused on the hematopoietic defects in the ΔTAD/ΔTAD embryos, these mice
exhibited a variety of developmental defects, culminating in embryonic death. Through
histological analysis of the ΔTAD/ΔTAD embryos at E18.5, we demonstrated the
importance of the Notch1 TAD in cardiac development. While it is known that Notch
signaling is required for OFT formation, as evidenced by the association of mutations of
the Notch signaling pathway with OFT defects and cardiac disease (Rentschler et al.,
2010; Rochais et al., 2009), our data suggest that Notch1 is the critical receptor for
proper OFT formation (Oda et al., 1997). Whether the effect on cardiac development
results from specific TAD signals or the overall decrease in embryonic Notch1 signaling
remains to be determined.
The fact that ΔTAD mice do not die at E9.5, as occurs with the complete loss of Notch1,
indicates that the TAD is not essential for all Notch functions. It follows that although the
TAD plays an important role in enhancing Notch1 target gene expression, it is likely
dispensable for expression of a subset of Notch targets that exceed a critical threshold
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for downstream functions. This is evident not only with our in vitro experiments using
ΔTAD MEFs where Hes1 is expressed at reduced levels in TAD deficient-cells, but also
in the defects of T cell development as seen in recipient mice reconstituted with
ΔTAD/ΔTAD HSCs, and in the failure of ΔTAD to drive leukemia in BM transduction
experiments. (Aster et al. 2000). Our ex vivo analysis of GSI-sensitive targets in FL
HSCs suggests that Notch targets in FL HSCs differ from T cells and provide a starting
point to elucidate how Notch functions in FL HSCs. It is tempting to speculate that
conditions of stress, such as reconstitution in a competitive environment or serial
transplantation, both of which require rapid expansion, could necessitate increased
Notch target gene expression, which is compromised in the absence of the TAD. While
there are likely many Notch1 TAD dependent genes, our initial studies on MEFs have
identified Hes1 as a model target gene that is dependent on TAD function. Our data also
reveal that the TAD is important for the proper assembly of the Notch1/RBPJ/MAML
complex that is required for Notch-induced transcription (Gordon et al. 2008). Using
+/ΔTAD MEFS, we demonstrate preferential binding of both Notch1 and Maml1 to the
wildtype protein even though the ΔTAD protein was present in excess. The decreased
binding of Maml1 is particularly striking, as Maml is required to create a stable ICN/Rbpj
complex (Nam et al. 2006; Wilson and Kovall 2006). The simplest explanation would be
for the TAD to have a role in the formation of contacts that stabilize the complex (Nam et
al. 2006; Wilson and Kovall 2006).
Activation of the Notch pathway in vitro by ligand stimulation has been employed to
expand hematopoietic progenitors from human cord blood HSCs, demonstrating that
manipulation of the Notch pathway is a viable and effective therapeutic strategy
(Varnum-Finney et al. 2011). Ex vivo expansion of murine HSCs has also been achieved
using a method that relies on the presentation of Notch-ligands on endothelial cells
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(Butler et al. 2010). Although these examples point to the potential that the Notch
signaling pathway represents, studies to date had not provided a clear indication that
physiologic Notch signaling is essential for HSC homeostasis beyond establishing the
first definitive LT-HSC. Our data show that Notch1 exerts important functions in FL
HSCs. Since the current attempts to expand HSCs ex vivo recapitulate embryonic
hematopoiesis, identification of Notch as a critical player in this process provides a new
rationale for studying Notch in this clinically relevant context. Recent data suggest that
enhanced Notch signals in the adult BM promote HSC differentiation at the expense of
self-renewal (Chiang et al. 2013; Lee et al. 2013). Our current data show that in the FL,
enhanced Notch signals are compatible with both HSC expansion and self-renewal. Our
current findings extend our understanding of the crucial crosstalk between hematopoietic
development and Notch biology with regard to FL HSC expansion and maturation.
	
  

	
  

	
  
	
  
	
  
	
  
	
  

	
  

71	
  

	
  

	
  

Chapter 3: Conclusions and Future directions

	
  

	
  
Summary of findings
How the FL supports expansion of HSCs is an area of considerable interest, as a greater
understanding of how HSCs expand in vivo could lead to the development of ex vivo
expansion strategies. Notch1 plays essential roles in mammalian development. In the
hematopoietic system, Notch1 is required to generate the first HSCs in the developing
embryo. Shortly after HSCs are formed in the embryo, they transit to the FL and undergo
robust expansion. Although a number of experimental systems have been devised to
alter Notch1 activity in vitro and in vivo, the role of Notch in HSCs after early embryonic
emergence remains unknown. Multiple pieces of data allude to a requirement for Notch1
signaling in the FL, but a specific role for Notch signaling in FL hematopoiesis has not
been identified due to early embryonic lethality of Notch1-null mutants. To address this,
we took advantage of a mouse model with genetic deletion of the Notch1 transcriptional
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activation domain (TAD). ΔTAD/ΔTAD embryos had hypomorphic Notch1 activity and did
not survive past late gestation, but were able to generate functional FL HSCs in midgestation. This allowed us to interrogate the effect of reduced Notch1 activity on FL
HSCs, revealing a novel role for Notch1 in FL HSC survival and providing evidence that
Notch1 influences FL HSC function. Study of the ΔTAD/ΔTAD mice also revealed that
the TAD contributed to Notch1 dependent developmental processes such as
cardiovascular OFT and T cell development. The TAD was previously reported to
contribute to Notch1 activation through association with transcriptional co-activators. We
confirmed that loss of the TAD dampened the ability of Notch to activate transcription in
vitro, and proposed a transcriptional mechanism where the TAD may also be required
for optimal formation of the Notch transcription complex (NTC).

The Notch1 TAD and transcription
	
  
The Notch1 TAD, together with the ANK domain, can interact physically and functionally
with the transcriptional co-activators PCAF/GCN5 in vitro (Kurooka and Honjo 2000). It
has yet to be determined if these interactions occur in vivo or if recruitment of PCAF is
central to activation by the TAD. In addition to co-activator binding, we present a model
where the TAD helps to optimally form the Notch transcription complex. This could
account for the decreased activity of the ΔTAD protein in vivo, even though it is more
abundant than wild type ICN1. It is also interesting to speculate, that if transcription is
coupled to phosphorylation and degradation of ICN1, that the accumulation of the ΔTAD
protein could be secondary to decreased binding and subsequent degradation at target
promoters.	
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While our studies are limited to the analysis of Notch1 binding to a short stretch of
promoter DNA of a single Notch target, these results add to the general understanding of
the

Notch1

TAD

mechanism

of

function.

Future

studies,

using

chromatin

immunoprecipitation experiments in ΔTAD/ΔTAD cells, will interrogate if NTC formation
and stabilization are hampered in ΔTAD/ΔTAD cells in vivo, and if this mechanism is
conserved in other promoters of Notch targets, especially for putative TAD dependent
genes, such as Jag1.

Target specificity of the TAD
	
  
The differences in development between Notch1 null and the N1 ΔTAD/ΔTAD embryos
indicate that there are Notch1 functions in vivo that do not depend on the TAD, and that
the TAD is not essential for basal Notch1 activation. A few scenarios that could account
for the apparent specificity of the TAD in Notch1 dependent developmental events are
as follows: The TAD may support activation of certain targets, possibly mediated by the
presence of additional co-activators at specific genes. Alternatively, the TAD may
globally augment transcription of Notch targets, but the transcriptional threshold of
certain Notch targets is achieved without the TAD. To identify interacting proteins using
liquid chromatography-mass spectrometry, we are performing tandem IPs using tagged
versions of ICN and ICNΔTAD as molecular baits. By comparing proteins that interact
differentially with ICN and ICNΔTAD, we can ascertain if there are specific binding
partners that may affect transcription of TAD dependent genes. While it is difficult to
differentiate between these possibilities, future experiments aimed at identifying binding
partners of the TAD and genetic profiling of ΔTAD/ΔTAD cells should provide a more
complete picture of how the TAD influences transcriptional activation by Notch1.
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In our experiments utilizing retroviral expression of ΔTAD in the 8946 cell line, we found
that deletion of the TAD resulted in sub-optimal expression of every gene that we
measured, implying that the TAD may globally enhance Notch1 dependent description.
This result is consistent with our biochemical data where deletion of the TAD affected
the core complex assembly on the DNA. Together, these findings lead to a model where
the TAD is generally required for activation, possibly by affecting stability of the NTC.
The fact that ΔTAD mice do not recapitulate the early embryonic death that occurs with
complete loss of Notch1 function, demonstrates that, even if the TAD plays an important
role in globally enhancing Notch1 target gene expression, there are subsets of Notch
target genes that do not require the TAD to maintain sufficient levels of activation for
downstream function. Identification of the genes dependent on the TAD in vivo could
inform us of the activation thresholds for genes downstream of Notch1 in HSC
generation, OFT formation, T cell development and T-ALL.

Development of ΔTAD/ΔTAD embryos

We found that embryos lackig the Notch1 TAD do not to survive past birth. There also
appears to be a partially penetrant lethality by mid-gestation of ΔTAD/ΔTAD embryos,
which may be due in part to multiple defects in the cardiovascular OFT.. Inhibition of
Notch signaling in cells of the second heart field (by specific expression of DNMAML)
also disrupts OFT formation. These embryos, however, are able to survive to late
gestation. Because the ΔTAD/ΔTAD is a constitutive mutation, it is likely the severity and
scope of developmental defects are greater than those in mice with conditional Notch
inhibition.
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We found decreased expression of Hes1 and Jag1 in Notch1 TAD deficient MEFs. Both
of these genes are implicated cardiovascular OFT development (High et al. 2008; High
et al. 2009; Rochais et al. 2009), making them attractive candidates for genes regulated
by the Notch1 TAD in OFT formation. We also identified Efna1 (Ephrin A1) as a Notch
sensitive target. Albeit the Notch dependent expression of Eprin A1 was observed in
HSCs, its expression in the cardiovascular system position Ephrin-A1 as an interesting
potential target of the Notch1 TAD in the vasculature and OFT (McBride and Ruiz 1998;
Frieden et al. 2010).
Aside from the cardiovascular tract defects, the ΔTAD/ ΔTAD embryos appear grossly
normal, but it is possible that we have overlooked developmental defects with the
histological analysis that we performed. In particular, Notch1 is crucial to vasculogenesis
and arterial specification, both of which are required for survival past E10.5. Ephrin B2 is
downstream of Notch in arterial specification (Lawson et al. 2001) and it remains to be
tested if the TAD is important for transcription of this gene and if vasculogenesis is
perturbed in ΔTAD/ ΔTAD embryos.

Notch1 TAD function and gene targets in HSCs
	
  
We observed a reduction in the number and reconstitution capacity of Notch1 TAD
deficient HSCs in the E14.5 FL. The decrease of HSCs in ΔTAD/ΔTAD FL appeared to
be due to a survival defect and not reduced proliferation. Because the Notch1 TAD
deletion is a constitutive mutation, it is possible that these survival defects are inherited
prior to entering the FL. We determined that phenotypic HSCs are generated in the AGM
of ΔTAD/ΔTAD embryos, but have not characterized these cells beyond expression of
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cell surface markers used for their identification. Pharmacological inhibition of Notch in
AGM explants induces cell death, consistent with a role for Notch in early HSC survival
(Richard et al. 2013). Additional functional analyses of ΔTAD/ΔTAD HSCs at earlier
development times should shed light on this. It is also conceivable that cell nonautonomous defects in the ΔTAD/ΔTAD HSCs. As Notch1 TAD is deleted from all cells
in the embryo, it could lead to changes in the FL HSC niche and/or vasculature, which
impact survival of FL HSCs.
We found that sorted FL HSCs and transplant-derived BM HSCs from ΔTAD/ΔTAD FL
cells failed to reconstitute recipients as efficiently as wild type cells. This supports a cell
intrinsic requirement for Notch1 and the Notch1 TAD for HSC function. We have yet to
determine if loss of the Notch1 TAD impacts homing, self-renewal, proliferation, or
survival of transplanted HSCs. As all of these processes are critical for hematopoietic
reconstitution, defects in any of them could account for the impaired reconstitution
exhibited by ΔTAD/ΔTAD FL HSCs. The fact that ΔTAD/ΔTAD-derived BM HSCs also
fail to efficiently reconstitute in secondary transplants points to insufficient HSC selfrenewal. Initially, we plan to test if ΔTAD/ΔTAD FL HSCs have a defect in self-renewal.
To address this question, we will treat non-competitive ΔTAD/ΔTAD FL transplant
recipients in vivo with 5-fluoruracil (5-FU), a myeloablative agent that depletes cycling
hematopoietic cells, yet spares quiescent HSC (Berardi et al. 1995; Randall and
Weissman 1997). Although quiescent HSCs are initially resistant to 5-FU cytotoxicity,
they are driven into the cell-cycle and depleted after repeated doses (Berardi et al. 1995;
Randall and Weissman 1997). We predict that if the TAD is required to maintain HSC
self-renewal, then they will be prone to 5-FU induced hematopoietic failure.
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Importantly, the reconstitution defects that we uncovered in ΔTAD/ΔTAD FL HSCs and in
BM HSCs derived from ΔTAD/ΔTAD cells substantiate a role for Notch1 in HSC function.
Ultimately, we will perform genetic profiling of the ΔTAD/ΔTAD FL HSCs to better identify
the relevant Notch1 targets in this population. Because we are only able isolate very few
SLAM LSKs from the FL of these embryos, we chose to first identify putative FL HSC
Notch targets in wild type FL HSCs. To do this, we cultured FL HSCs ex vivo in
conditions that stimulated or inhibited Notch signaling. Genetic profiling of wild type FL
HSCs lead to the identification of Hes1, Itgal/LFA-1, and Jag1 as a potential Notch target
in the FL. Important roles for these genes in HSC generation and function have been
reported (Asaumi et al. 2001; Robert-Moreno et al. 2008; Guiu et al. 2013). If their
expression is coordinately reduced in ΔTAD/ΔTAD HSCs, this could contribute defects
we observed. After we establish the candidate HSC targets of the TAD, we will use
genetic knockdown or inhibition to confirm their functional significance in hematopoietic
reconstitution.

Notch1 TAD and T cell development
	
  
Notch1 is required for T cell specification of hematopoietic progenitors and progression
past the DN3 stage to become DP thymocytes (Radtke et al. 1999; Sambandam et al.
2005; Maillard et al. 2006). We found that FL HSCs deficient in the Notch1 TAD are able
to produce T cells, but not as efficiently as wild type FL HSCs. Specifically, we observed
decreased percentages and absolute numbers of DP derived ΔTAD/ΔTAD cells in the
thymus of reconstituted recipients. This is in contrast to phenotypes observed with loss
of Notch1, where BM progenitors lacking Notch1 do not progress past the DN1 stage in
the thymus (Radtke et al. 1999; Sambandam et al. 2005), and later deletion of Notch1
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blocks progression to the DP stage (Maillard et al. 2006). A T cell phenotype similar to
that of the ΔTAD/ΔTAD has been reported in experiments using Notch1+/- mutants. (Tan
et al. 2005). This is consistent with the Notch1 TAD acting to globally enhance
expression of downstream Notch targets in T cells, and suggests that the Notch1 TAD is
necessary to achieve the threshold of Notch1 activity for efficient T cell development.
In the future, gene expression analysis of thyomcytes derived from ΔTAD/ΔTAD cells
and of cells expressing ICN1ΔTAD should provide a more complete picture of genes
regulated by the Notch1 TAD, and help to create a landscape of activation thresholds for
Notch1 targets in physiologic T cell development and T-ALL. Hes1 and c-Myc, are both
reliant on the TAD for optimal expression in vitro. Since these genes are essential for T
cell development and transformation (Weng et al. 2006; Wendorff et al. 2010; De
Obaldia et al. 2013), they are enticing candidates for regulation by the Notch1 TAD in T
cells and in the context of T-ALL.

Concluding remarks
	
  
We have demonstrated an essential role for the Notch1 TAD in cardiovascular
development, fetal HSC survival and function, and T cell development. Further
characterization of the ΔTAD/ΔTAD embryos should reveal if the Notch1 ΔTAD is
required for additional developmental events. We believe that the hypomorphic nature
ΔTAD/ΔTAD mutation stems from a general reduction in the transcriptional activity of
Notch1, resulting in decreased expression of Notch targets with high activation
thresholds for transcription. Thus, the ΔTAD/ΔTAD mouse model represents a useful tool
to study Notch1 dependent transcription, and insights gained from study of the Notch1
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TAD could lead to a more refined catalogue of relative activation thresholds of genes
downstream of Notch1 activation. A thorough understanding of the Notch signaling
events important for hematopoietic development and HSCs homeostasis is essential to
the development of therapeutic strategies and clinical applications of a wide variety of
hematological disorders.
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Chaper 4: Methods

Mice
ΔTAD/ΔTAD mice were generated by mutation of the Notch1 gene in embryonic stem
cells using homologous recombination. The Notch1 TAD is from bp 43091-43699 of the
mouse Notch1 gene, between an Xho1 and Sac1 restriction sites. The Notch1 TAD
deletion is from bp 6580-7188 of the mouse Notch1 coding sequence (this region
encompasses the glutamic acid at amino acid position 2193 to valine at amino acid
2396). A gene-targeting vector was constructed to mediate PCR-directed deletion of the
TAD from mouse Notch1. The targeting vector also introduced an EcoR1 site in the
mutant TAD exon. Thus, the amino acid sequence resulting from the mutant TAD region
was MLSPVDSLGILSSAANGH. The targeting vector was transfected into mouse ES
cells and clones with deletion of the Notch1 TAD were injected into blastocysts. Mice
with germline transmission of the Notch1 TAD deletion were selected for breeding and
backcrossed to the C57BL/6 background for greater than 6 generations. The Extract-NAmp Tissue PCR Kit (Sigma XNAT2) was used to genotype adult and embryonic tissue.
Notch1in32 mice (Swiatek et al. 1994), on a C57BL/6 background, were provided by Jan
Kitajewski, Columbia University. B6-Ly5.2/Cr (Strain Code 01B96) mice were obtained
from the Frederick National Laboratory of the NCI. CD45.1+/CD45.2+ mice were obtained
from the first generation of matings between C57BL/6 and B6-Ly5.2/Cr mice. Rbpjf/f;
Vav1-CreRosa26YFP mice were on a C57BL/6 background. Vav1-Cre mice (Stadtfeld
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and Graf 2005)	
  were provided by Thomas Graf, CRG, Barcelona. Genomic DNA from
yolk sac tissue was used for genotyping by PCR. All mice were housed in specific
pathogen-free facilities at the University of Pennsylvania or the Parc Recerca Biomedica
Barcelona (PRBB) animal facility. Experiments were performed according to the
guidelines from the National Institutes of Health with approved protocols from the
University of Pennsylvania Animal Care and Use Committee or with approved protocols
from PRBB Committee and Generalitat de Catalunya.

Cell culture
MEFs were generated following standard protocol (Conner 2001). Cells were grown in
DMEM (Cellgro) supplemented with 10% FBS (Gibco), 1% Penicillin/Streptomycin
(Gibco), 1% L-glutamine (Gibco), 100µM 2-mercaptoethanol (Sigma), and 1% NEAA
(Gibco). MEFs were not used beyond passage 25. Primary CD4 cells were cultured for
48 hr in the presence of T-cell-depleted splenocytes (as source of antigen presenting
cells) at a T-cell:splenocyte ratio of 1:4. Soluble anti-CD3 (eBio 145-2C11) and antiCD28 (eBio 37.51) were added at 1ug/mL. T-cell culture media was IMDM (Gibco)
supplemented with 10% FBS, 1% Penicillin/Streptomycin and 1% L-glutamine and rIL-2
(5ng/mL) (Peprotech). OP9-DL1 cells were maintained in OP9 media: MEM-Alpha
(Gibco) supplemented with 20% FBS (Hyclone), 1% Penecillin/Streptomycin, 1% Lglutamine, and 1% NEAA. For short-term culture of HSCs, 500,000 OP9-DL1 cells were
seeded in 10 cm plates in OP9 media with 5% FBS. 15 million RBC lysed E14.5FL cells
were added to OP9-DL1 cells and cultured in OP9 media with 5% FBS, Flt3 (5ng/mL)
(PeproTech) and mSCF (100ng/mL). (PeproTech) in the presence of GSI (EMD,	
  γSecretase Inhibitor XXI, Compound E) (1µM) or DMSO for 4 hr or 10hr. Non-adherent
cells were collected and stained for CD45.2 and SLAM-LSK markers. GFP– (to exclude
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contaminating OP9-DL1 cells) CD45.2+ SLAM-LSK cells were sorted into 200µL of
Arturus Pico Pure Extractrion Buffer for RNA preparation.

8946 cell culture and transduction
8946 cells were maintained in RPMI supplemented with 10% fetal bovine serum
(Hyclone), 2mM L-glutamine, 1mM sodium pyruvate, and antibiotics. Production of hightiter retrovirus MigR1 control, Mig-ICN1, and Mig-ICN1 ΔTAD were produced as
described (Pear et al. 1996). Cells were centrifuged with the appropriate amount of viral
supernatant and 4µg/mL hexadimethidrine bromide (Sigma) at 25o C for 90 min at 2500
rpm. GFP+ cells were sorted 48 hr post transduction. Sorted cells were treated with
doxycycline (20ng/mL) for 24 hr to suppress the human MYC transgene, a timepoint that
did not affect 8946 cell viability. Cells were then harvested for RNA preparation and
qPCR was performed to measure mRNA expression of the indicated genes. mRNA
expression values are absolute and normalized to Ef1a. GFP expression after
doxycycline treatment was also confirmed by flow cytometry

Western analysis
Nuclear lysates were prepared using the Active Motif Nuclear Complex Co-IP Kit
(54001) and whole cell lysates were prepared with RIPA buffer; protease inhibitors were
included for both. Protein concentration was determined with the BioRad Protein Assay
Dye Reagent (BioRad). Proteins were separated using SDS-PAGE and transferred to
PVDF membranes. Antibodies used for Western blot were Cleaved Notch1 (Val1744)
Antibody (Cell Signaling Technology #2421), MAML1 (D3E9) Rabbit mAb (Cell Signaling
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Technology #11959), β-actin (Sigma), and secondary anti-mouse-HRP (Pierce) or antirabbit-HRP (Pierce). Blots were visualized with SuperSignal West Pico
Chemilumenscence (Thermo Scientific) or SuperSignal West Femto Chemilumenscence
Substrate (Thermo Scientific).

Oligonucleotide pull-down
MEFs generated from embryos of the same litter were isolated as described above, and
grown to similar early passages (P6-9). Adherent MEFs were trypsinized, washed twice
in PBS, centrifuged and resuspended in hypotonic buffer for nuclear extraction per the
manufacturer’s recommendation (Active Motif #54001). Nuclear protein lysates were
quantified by Bio-Rad Bradford assay. 100-150µg of protein were incubated with
annealed biotinylated oligonucleotides at 2µg/µL for 4-12 hr at 4o C with rotation. Lysate
and biotinylated oligonucleotide mixture was supplemented with poly-IC (1µg/µL) and
the volume was brought up to 500µL by addition of binding buffer (12mM HEPES, 4mM
Tris, pH 8.0, containing, 60mM KCl, 5% glycerol, 500uM EDTA, 1mM DTT and 1x
protease inhibitors (Roche). Streptavidin beads (Invitrogen) were washed twice in
Binding Buffer and 25-30µL of beads were added to the nuclear lysate and biotinylated
oligonucleotide mixture and incubated for 4-8 hr at 4oC with rotation (Puente et al. 2011).
Incubated mixture was centrifuged for 1min at 6000 rpm, and the supernatant was
collected and stored at -80oC. Beads were washed 4x in 1mL of binding buffer and
resuspended in 25µL of Laemmli buffer, boiled at 100o C for 10 min, and centrifuged for
10 min at 13,000 rpm. Eluted proteins were separated by SDS-PAGE in a 7-8% gel and
Western blot was prepared with cleaved Notch1 (Val1744) antibody as described above.
Oligonucleotide sequences are provided in the supplement (Table S1).
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Flow cytometry and cell sorting
AGMs, FL or BM cells (from adult tibia and femurs) were harvested, and resuspended in
PBS supplemented with 10% heat inactivated FBS (Gibco) and 1%
Penicillin/Streptomycin (Gibco). Antibodies used for identification of HSCs in E11.5 AGM
and E11.5 FL cells were CD144 Alexa Fluor® 647 (eBioscience BV13), CD45.2 V450
(BD 104), 7AAD (eBioscience), and TER-119 PerCP-Cy5.5 (BD TER-119). E11.5 AGM
single cell suspensions were prepared by treating with collagenase, type I (Sigma) prior
to staining. For SLAM-LSK staining, antibodies used were: CD45.2 FITC (104), Sca-1
(Ly6A/E) PerCP-‐Cy5.5 (eBioscience D7), CD48 APC (eBioscience HM48-1), CD150 PECy7 (Biolegend TC15-12F12.2), c-Kit APC-Cy7 (eBioscience 2B8), and DAPI (BD).
Lineage markers for BM cells were B220 (BD RA3-6B2), Gr-1 (BD RB6-8C5), CD3 (BD
17A2), TER-119 (BD TER-119). Mac-1 (BD M1/70), CDllC (BD HL3). NK1.1 (BD
PK136), CD4 (BD RM4-5), CD8α (BD 53-6.7), CD19 (BD 1D3), all conjugated to
phycoerythrin (PE). Lineage markers used for FL cells were B220 (BD RA3-6B2), Gr-1
(BD RB6-8C5), CD3 (BD 17A2), and TER-119 (BD TER-119), all conjugated to PE. For
intracellular cleaved Notch1 detection, cells were first stained for surface markers, then
fixed and permeabilized using the eBioscience Transcription Factor Staining Buffer Set
(00-5523). Fixed/permeabilized cells were incubated with primary rabbit antibody to
Notch1 cleaved at Val1744 (Cell Signaling #2421) at a 1:100 dilution in permeabilization
buffer and secondary Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) (Invitrogen) at a
1:300 dilution in permeabilization buffer. Surface Notch was detected by anti-Notch1
(eBioscience 22E5) conjugated to APC.

For Annexin V detection, cells were first stained for SLAM-LSK markers (Lineage
markers were conjugated to V450), then incubated with Annexin V (PE) in binding buffer
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provided in the Annexin V Apoptosis Detection Kit (eBioscience 88-8102-72). 7-AAD
Viability staining solution (eBioscience) was added to cells prior to analysis. Lin+ FL cells
were used as an internal control to determine the percentage of Annexin V+ FL LSKs
and SLAM-LSKs in each sample. Values were determined by subtracting the mean
percentage of +/+ Annexin V+ Lin+ cells (calculated as % Annexin V+ cells ± SEM, which
was 1.600 ± 0.147, n=4) from the mean percentage of Annexin V+ +/+ SLAM-LSKs, and
by subtracting the mean percentage of ΔTAD/ΔTAD Annexin V+ Lin+ cells (4.025 ± 0.728,
n=4) from the mean percentage of Annexin V+ ΔTAD/ΔTAD SLAM-LSKs.

Cell cycle analysis was performed by first staining for SLAM-LSK markers. Cells were
not stained for CD45.2 for cell cycle analysis. Cells were then fixed and permeabilized
using the eBioscience Transcription Factor Staining Buffer Set followed by incubation
with DAPI and Ki-67 FITC (eBioscience SolA15) at a 1:200 dilution. Cells were analyzed
on a BD LSRII equipped with an ultraviolet laser. Acquisition was performed with DAPI
on linear scale. Acquisition for flow cytometry was performed on a LSRII (Becton
Dickinson). All cells were sorted on a BD FACSAria into PBS supplemented with 2%
FBS and 1% Penicillin/Streptomycin. All flow cytometry data was analyzed with FlowJo
(TreeStar). LT-HSC numbers were calculated from the number of cells within the live cell
gate. LSK (DAPI-Lin–Sca1+Kit+) or SLAM-LSK (DAPI-Lin–Sca1+Kit+CD48-CD150+) cells
from E14.5 FL were acquired on a BD LSRII flow cytometer.

HSC transplants
For non-competitive transplants, unfractionated FL cells or sorted SLAM-LSK FL cells
from E14.5 embryos (C57BL/6) were transplanted I.V. with congenic splenocyte support
cells into congenic recipients. Red blood cells were lysed with ACK lysing buffer (Lonza).
For competitive transplants of ΔTAD/ΔTAD cells, unfractionated FL cells (1 x 106 cells) or
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sorted SLAM-LSK FL cells (350 cells) from E14.5 embryos (C57BL/6) were transplanted
I.V. into congenic recipients with equal numbers of unfractionated FL or sorted BM
SLAM-LSK. Live/dead cells were identified by DAPI staining. For secondary transplants,
1000 donor derived +/+ or ΔTAD/ΔTAD CD45.2+ SLAM-LSKs were sorted from the BM
of primary transplant recipients (primary transplant was non-competitive E14.5 FL cell
transplant) and transplanted with congenic splenocyte support cells into congenic
recipients. For Rbpj f/f; Vav-Cre Rosa26YFP competitive FL transplants, 10,000
nucleated E14.5 FL cells from Rbpj f/f; Vav-Cre Rosa26YFP or Rbpj +/+; Vav-Cre
Rosa26YFP were transplanted with 200,000 nucleated BM competitor cells. Rbpj
deletion in FL-engrafted cells was confirmed by PCR on genomic DNA prepared from
purified sorted BM YFP+ cells obtained 4 months post-transplantation.	
  All cells were
washed with cold PBS prior to injection. Mice were maintained on antibiotic water for 2
wks post-transplant.

Statistical analysis
For ΔTAD/ΔTAD competitive FL transplants, regression analysis was performed to
evaluate the difference of mean CD45.2 percentage in reconstituted recipients.
Experiment and genotype were treated as independent factors. For non-competitive FL
transplants, two-way analysis of variance was used to calculate significance of mean
CD45.2 reconstitution. For Rbpj f/f; Vav-Cre Rosa26YFP competitive FL transplants, the
data were transformed using the arc-sine transformation of the observation/100. The ttest was used to evaluate the difference between the transformed mean reconstitution
from the Rbpj f/f; Vav-Cre Rosa26YFP and Rbpj +/+; Vav-Cre Rosa26YFP cells. Unless
noted, the Student’s t-test was used to calculate the p-value in all other experiments.
Welch-Satterthwaite’s method was used when there was evidence of unequal variances
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in the two groups. All error bars represent SEM. All statistical analysis was performed
with SAS/STAT software, Version 9.3 of the SAS System for Windows and GraphPad
Prism Version 5 for Mac.

Quantitative PCR
RNA was extracted using the QIAGEN RNeasy Mini or Micro Kit. For SLAM-LSKs, cells
were sorted into 200uL of Arcturus Pico Pure Extraction Buffer and RNA was prepared
using the Arcturus Pico Pure RNA extraction kit (Life Technologies KIT0204). cDNA was
synthesized from RNA with the Superscript II kit (Invitrogen). Transcripts were amplified
with Sybr Green PCR Master Mix (Applied Biosystems) and quantitative PCR was
performed on the ABI Prism 7900HT system (Applied Biosystems). Absolute quantities
of mRNA were normalized to ef1-alpha. Primer sequences are provided in the
Supplement.

Mircroarray analysis of SLAM-LSKs
SLAM-LSKs were sorted into 200uL of Arcturus Pico Pure Extraction Buffer. RNA from
SLAM-LSKs was extracted using the Arcturus Pico Pure RNA extraction kit. Microarray	
  
services	
  were	
  provided	
  by	
  the	
  UPENN	
  Molecular	
  Profiling	
  Facility,	
  including	
  quality	
  control	
  tests	
  
of	
  the	
  total	
  RNA	
  samples	
  by	
  Agilent	
  Bioanalyzer	
  and	
  Nanodrop	
  spectrophotometry.	
  All
protocols were conducted as described in the NuGEN Ovation Pico WTA system v2 user
guide and the Affymetrix GeneChip Expression Analysis Technical Manual. Briefly, 10ng
of total RNA was converted to first-strand cDNA using reverse transcriptase primed by
poly(dT) and random oligomers that incorporated an RNA priming region. Second-strand
cDNA synthesis was followed by ribo-SPIA linear amplification of each transcript using
an isothermal reaction with RNase, RNA primer and DNA polymerase, and the resulting
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ssDNA was assessed by Bioanalyzer, fragmented and biotinylated by terminal
transferase end labeling. ssDNA yields ranged from 7.8-11.3mll protocols were
conducted as described in the on
NuGEN Ovation Pico WTA system v2 user guide and the Affymetrix GeneChip Expressi
on Analysis Technical Manual. Briefly, 10ng of total RNA was converted to first-strand

cDNA using reverse transcriptase primed high (100mM MES, 0.1M NaCl) stringency an
d stained with streptavidin-phycoerythrin. Fluorescence was amplified by adding biotinyl
ated anti-streptavidin and an additional aliquot of streptavidin-phycoerythrin stain. A conf
ocal scanner was used to collect fluorescence signal after excitation at 570 nm.	
  

Data collection analysis
Final microarray analysis reflects data from 7 biologically independent experiments (for
4hr GSI time point) and 4 independent experiments (for 10 hr analysis). All data obtained
from the 4hr GSI time course and 10hr time course were analyzed independently of
each other. CEL files were analyzed using Partek Genomics suite. Separately for each
analysis, Affymetrix .cel files (containing probe intensities) were exported from
Command Console software and imported into Partek Genomics Suite (v6.6, Partek Inc.,
St. Louis, MO) where RMA was applied yielding normalized, log2 transformed signal
intensities. Transcript IDs were filtered to exclude technical controls, leaving 34,365 IDs
for differential expression analysis. To find differentially expressed genes, SAM
(Significance Analysis for Microarrays, samr v2.0, Stanford University) was applied using
a two-class (GSI vs DMSO) paired (by experiment) design. Fold change and q-value
(representing false discovery rate) were calculated for all transcript IDs. Genes were
prioritized based on q-value and fold-decrease in GSI vs DMSO treatment. Excel
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datasets are available in the supplement and raw data files will be provided on the GEO
Database accession # GSE53713

Histology
Samples were fixed overnight with 4% paraformaldehyde, dehydrated through an
ethanol series, and subsequently paraffin-embedded and sectioned. Hematoxylin and
eosin staining was performed using standard protocols. Images were analyzed using
Adobe Photoshop (sizing, brightness or contrast adjustments, etc.). Brightness and
contrast was adjusted linearly across the entire image for any particular image.

	
  
	
  
	
  

Primer	
  and	
  oligonucleotide	
  sequences	
  
	
  
	
  
qPCR	
  primers	
  
	
  	
  
Hes1	
  Forward	
  
Hes1	
  Reverse	
  	
  
	
  	
  
Ef1	
  alpha	
  Forward	
  	
  
Ef1	
  alpha	
  Reverse	
  	
  
	
  	
  
Notch1	
  Common	
  Forward	
  Primer	
  
Notch1	
  Reverse	
  +/+	
  	
  
Notch1	
  Reverse	
  DTAD/DTAD	
  	
  
	
  
	
  
	
  Jag1	
  F	
  

5’	
  GAA	
  AGA	
  TAG	
  CTC	
  CCGGCA	
  TT	
  3’	
  
5’	
  GTC	
  ACC	
  TCG	
  TTC	
  ATG	
  CAC	
  TC	
  3’	
  
	
  	
  
5’	
  CAC	
  TTG	
  GTC	
  GCT	
  TTG	
  CTG	
  TT	
  3’	
  
5’	
  GGT	
  GGC	
  AGG	
  TGT	
  TAG	
  GGG	
  TA	
  3’	
  
	
  	
  
5’	
  AAG	
  GGC	
  TGG	
  CTT	
  GTG	
  GTA	
  G	
  3’	
  
5’	
  CGA	
  GGC	
  CAC	
  ATC	
  TGA	
  CAA	
  GT	
  3’	
  	
  
5’	
  CCG	
  AGC	
  TGA	
  GAA	
  TTC	
  CGA	
  GG	
  3’	
  
	
  

Jag1	
  R	
  

	
  	
  
5’	
  GGTAACACCTTCAATCTCAAGGC	
  3’	
  
5’	
  GGTCCTACACTTTGCTGGTGG	
  3’	
  

Itgal	
  F	
  

5’	
  GCAAAGTCGACCTGGTGTTT	
  3’	
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Itgal	
  R	
  

5’	
  ACATCGGGGTTCTTGTTCTG	
  3’	
  

	
  

	
  

Oligonucleotides	
  

	
  	
  

Hes1	
  promoter	
  biotinylated	
  oligo	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  
Hes1	
  promoter	
  mutated	
  oligo	
  	
  
	
  	
  

5’-‐biotin-‐GTGTCTCTTCCTCCCATTGGCTGAAAGT	
  
TACTGTGGGAAAGAAAGTTTGGGAAGTTTCACAC	
  

GAGCCGTTCGCGTGCAGTCCCAGATATA	
  
	
  	
  
5’-‐biotinTATATCTGGGACTGCACGCGAACGGCTCGT	
  
GTGAAACTTCCCAAACTTTCTTTCCCACAGTAACT	
  
TTCAGCCAATGGGAGGAAGAGACAC	
  
	
  	
  

	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  
	
  	
  

5’-‐biotin-‐GTGTCTCTTCCTCCCATTGGCTGAAAGTT	
  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
A	
  
CCGTTCGCGTGCAGTCCCAGATATA	
  
	
  	
  
5’-‐biotin-‐TATATCTGGGACTGCACGCGAACGGTTT	
  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAACT	
  
TTCAGCCAATGGGAGGAAGAGACAC	
  
	
  	
  

Genotyping	
  primers	
  

	
  	
  

Notch1in32	
  Forward	
  
Notch1in32	
  (WT	
  allele)	
  Reverse	
  
Notch1in32	
  (Mutant	
  allele)	
  Reverse	
  
	
  	
  
TAD	
  forward	
  	
  
TAD	
  reverse	
  	
  

5’	
  TCT	
  AAG	
  TGC	
  TCC	
  GAG	
  GAG	
  ATC	
  A	
  3’	
  
5’	
  CAG	
  GGG	
  TTG	
  GAG	
  AGA	
  CAT	
  TCA	
  3’	
  
5’	
  TCG	
  CCT	
  TCT	
  ATC	
  GCC	
  TTC	
  TTG	
  3’	
  
	
  	
  
5’	
  GTT	
  GTA	
  CAT	
  CTG	
  CCT	
  GAC	
  TGG	
  GG	
  3’	
  	
  
5’	
  GTG	
  GTA	
  GCA	
  AGG	
  AAG	
  CTA	
  AGG	
  3’	
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Appendix
	
  

Appendix table 1: Frequency from +/N1in32 x ΔTAD/+ matings E9.5-E11.5
+/N1in32	
  

ΔTAD/+	
  

ΔTAD/N1in32	
  

8	
  

3	
  

9	
  

3	
  

	
  

	
  

	
  

3	
  of	
  3	
  embryos	
  
were	
  
*abnormal	
  	
  

Genotype	
  from	
  	
   +/+	
  
4	
  litters	
  
Total	
  #	
  
embryos	
  per	
  	
  
genotype	
  
	
  

	
  
*Abnormal phenotype - enlarged pericardial sac, smaller/less developed than other
embryos from litter, decreased vasculature in embryo and/or YS, (Notch1 loss of
function have increased cell death, decreased diameter of aorta, stunted development,
enlarged pericardial sac at E9.5-10.5 compared to WT).
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Figure 1. T cell and BM HSC percentage in +/ΔTAD adults. Phenotyping of thymus
and BM of 8 week +/+ and +/ ΔTAD adults.
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Figure 2. ΔTAD/ΔTAD LSKs can produce Thy1+ cells when cultured on OP9-DL1
cells. 350 LSK sorted from E14.5 FL and were plated into 1 well on OP9 DL1 with Flt3
and Il-7. Analysis at day 14, cells gated on live, singlet, GFP- (n= 1)
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Figure 3. Binding of MAML1 and Rbpj to Hes1 oligonucleotide in +/+, +/ΔTAD, and
ΔTAD/ΔTAD MEFs.
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Figure 4. Multi-lineage reconstitution from E11.5 AGM and FL transplant recipients
from +/+ and +/ΔTAD embryos. Unsorted cells from 1 E11.5 AGM from +/+ or +/ΔTAD
embryo were transplanted into 1 recipient. Peripheral blood was analyzed for expression
of the indicated markers at 12 weeks post transplant.

Figure 5. Reconstitution from E11.5 AGM and FL transplant recipients from +/+
and +/ΔTAD embryos.
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Figure 6. CD45.2 SLAM-LSK in Hes1 deficient FL cells. CD45.2+ SLAM-LSKs in
Hes1 +/- (n = 2) and Hes1 -/- (n = 2) E14.5 FL (n = 2). E14.5 FL (2 each from Hes1 +/and Hes1 -/- embryos) were RBC lysed and analyzed for expression of the indicated
markers.

Figure 7. Hes1 competitive FL transplant of sorted SLAM-LSK (4
weeks).Competitive FL transplant of 1000 CD45.2 SLAM-LSK Hes1 deficient cells. 1000
CD45.2+ SLAM-LSKs per embryo were sorted from Hes1 +/- (n = 2) and Hes1 -/- E14.5
FL (n = 2) and transplanted in competition with 1000 CD45.1/.2 BM SLAM-LSKs into
CD45.1 recipients.
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Figure 8. qPCR for mRNA expression of Endophilin A3 (Sh3Gl3), FasL, Hifa, and
Gata2 mRNA. E14.5 FL cells were cultured on OP9-DL1 cells for 4 hourss in the
presence of DMSO or GSI. SLAM-LSKs were sorted and used to make RNA.
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